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Abstract
Small molecule probes are useful tools for the study of biology. In particular, dye derived
fluorescence probes enable to spatiotemporally monitor the events of analyte of interest. The
noninvasive feature is particularly attractive for the biological studies in live cells. The
challenge is to develop chemical probes capable of detection of the analyte of interest with
high specificity.
Toward this end, my Ph. D. study centers on the development of novel chemical probes
for the study and understanding of the alternation of important cellar contents and substances
and their functions and relationship between normal and disease states. In the first effort, new
far-red organelle-targeting probes have been developed. They display excellent selectivity and
sensitivity in response to viscosity change in cell imaging studies. The probes are further
applied for the investigation of the correlation of elevated level of mitochondrial viscosity with
iv

mitochondrial damage in cellular and animal models. In the second effort, to investigate the
relationship between Fe(II) and mitochondrial damage in ischemic stroke, a new mitochondrial
targeting Fe(II) probe is designed, synthesized and evaluated by using a Fe(II) induced
cleavage of N-O bond chemistry. The relationship between the elevated level of Fe(II) and
ROS tied with the ischemia is uncovered by the probe using cellular and animal models. In the
third study, based on the unique N-O bond chemistry, a novel photo-triggered ketone prodrug
release system is designed and studied. The strategy can be used as a general approach to
spatiotemporally deliver drugs. Lastly, the role of iron (Fe(II) and Fe(III)) in the ferroptosis
process is elucidated. The studies reveal that that labile Fe(III) is the real ferroptosis inducer
instead of labile Fe(II) for the first time. Furthermore, hydroxylamines as new ferroptosis
inhibitors through the reduction of Fe(III) to Fe(II) are developed inspired by Fe(II) reduced
specific cleavage of N-O bond chemistry.
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Chapter 1. Introduction
1.1. Fluorescence probes
Fluorescence imaging has emerged as one of the most powerful techniques of the study of
biology, clinical diagnosis, drug discovery to s monitor targets of interest and biological
processes of a living system with high temporal and spatial resolution.1 Owing to easy access
and manipulation and less degree of disruption of biological systems, a number of small
molecular fluorescent probes for a variety of targets have been developed (Scheme 1.1) and
used for biological studies of living cells, tissues and animals.2-5 Many fluorescent probes have
been commercialized, and some have been established as the standard method for biomedical

Scheme 1.1. Selected fluorophores.

1

research.6
From chemistry point of view, great success has been achieved in development of
fluorescent probes. However, most of the reported fluorescent probes are far from practical
biological application. A biological useful probe should be: 1) able to work in aqueous
dominant biological media; 2) cell permeable with low toxicity; 3) excited and emitted at long
wavelength to minimize background fluorescence and cell radiation damage and detect deep
tissue;7 4) enough sensitivity and selectivity in complex circumstance in the cell with a low
concentration of target analyte; 5) able to target selected organelles, especially when the
organelle is closely related with target molecule, such as the viscosity probe for mitochondria
is necessary since the mitochondria is most viscous part in the cell;8,9 6) designed to meet strict
practical application to solve the real biological problems,10,11 rather than made new chemical
probes to verify their characters in simple chemical system.12-16

1.2. N-O chemistry
N-O bond is present in inorganic and organic compounds, from nitric acid to oxime.
Considering all five electrons in the second shell in the nitrogen atom. The oxidation state of
nitrogen is complex, from -3 to +5, which provides diversity of possible redox reaction for the
N-O single bond (Scheme 1.2). As a typically weak bond (average bond energy ABE(N-O): 201
kJ/mol vs ABE(C-H) 413 kJ/mol), N-O bond is prone to cleavage in a reaction. Based on the NO bond chemistry, a series of unique organic reactions have been developed, such as
Bamberger rearrangement,17 Beckmann rearrangement,18 Tiemann rearrangement,19 and
2

Polonovski-Potier reaction19 (Scheme 1.3).
The reaction with N-O bond cleavage can be classified into three categories based on the
redox character (Scheme 1.4):
1) reduction reaction: N-O bond is cleaved by the reductant such as Fe(II),20 Sm(II),21 and
Na(0)22, via a single electron transfer (SET) pathway.
2) homogenous cleavage: N-O bond was cut in the middle of the bond. one electron
Scheme 1.2 Examples of inorganic compounds and organic compounds with N-O bond

Scheme 1.3. Examples of named reaction involved N-O bond cleavage
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induced by transition-metal-mediated oxidative addition,23 (Pd, Cu, Rh, Ru, etc.) or lighttriggered cleavages such as UV,24 microwave,25 or visible light.26
3) Oxidation of N-O bond: It was an underdeveloped area with few reports, although the
standard iron content test has been established based on oxidation of N-O bond of
hydroxylamine by Fe(III) since 1926.27
Scheme 1.4. Three possible pathways of reaction via N-O bond cleavage

Scheme 1.5. our group’s Fe(II) responding functional molecule via N-O bond cleavage

Despite the long rich history of N-O bond chemistry, the application of such beautiful
chemistry to biological application is very limited. Most of the studies are associated with the
4

organic methodology. Taking advantage of the low bonding energy of N-O single bond, and
high selectivity towards Fe(II), our group has proven the possibility of N-O bond chemistry as
Fe(II) fluorescent probe and Fe(II) induced drug release system.28,29 In our continuing interest,
we further explore the N-O bond chemistry for the design of new chemical probes to
investigate biological systems.

1.3. Summary of thesis research
Aline with our group’s experience and expertise for the development of fluorescent probes
using unique N-O chemistry, I have been focusing on the design and development of new
functional small molecules for the study of biology. In the following chapters, I will detail the
effort towards the development of novel functional small molecules for organelle targeting
fluorescent probe for viscosity and Fe(II), the application for ferroptosis mechanism study, and
photo-trigger drug released by the blue LED light.

5

Chapter 2. Far-Red Fluorescence Rotors as Viscosity Probe
and Application in the Study of Ischemia/Reperfusion
Mitochondria Damage
Abstract
Intracellular viscosity is the key physical parameter for diffusion mediated cellular processes
such as transportation of mass and signal, interactions between biomolecules, and diffusion of
reactive metabolites. Subcellular detection for the viscosity of organelle is still hard due to the
size, targeting efficiency, and noise-signal ratio challenge. Because of this, we have developed
a group of new far-red sensitive and selective fluorescent probes for viscosity based on SiRhB
new fluorescence rotor structure, with high sensitivity, low toxicity, and far-red wavelength.
The probes display fast penetration across the cell membrane and are dramatically concentrated
accumulation in the cell. The targeting organelle is tunable from mitochondria to lysosomes
by simply changing of aromatic group of the probes. The results from these probes showed the
increase of mitochondrial viscosity for OGD/reperfusion model and Zn(II) induced respiration
inhibition in the cellular level. Finally, one of the probes was applied for the study of ischemic
stroke and hemorrhagic stroke in the animal model with observed viscosity change for the first
time.

6

2.1. Introduction

Viscosity, as one of the fundamental physical properties of liquids, is closely related to
diffusion. Taking advantage of the mechanical methods, viscosity measurements of bulk
biological fluids, such as lymphatic fluid,30 blood,31-33 and blood plasma,34,35 have been applied
or suggested for diagnosis as the signal of inflammations and tissue injuries from disease and
abnormalities. On the other hand, although intracellular viscosity is a key physical parameter
for diffusion mediated cellular processes such as transportation of mass and signal, interactions
between biomolecules, and diffusion of reactive metabolites,36 and the irregularity of this
parameter plays an important role in many different diseases.37-39 The studies for the relation
between intracellular and disease or abnormalities are very scare. Several detecting methods
of viscosity have been suggested,40,41 but subcellular detection for the viscosity of the
organelles, such as mitochondria or lysosome is difficult due to the challenges of size, targeting
efficiency and noise-signal ratio.42-45
Recently, a fluorescent rotor has been developed to measure viscosity employing
intramolecular torsional or rotational motion.46-58 Such fluorescent rotor comprises two
moieties of a fluorophore and a rotatable micro paddle, linked by a rotatable bind. In the low
viscosity environment, the paddle spins fast and quenches fluorophore via a photoinduced
electron transfer process (PeT). In the enhanced viscous environment, the rotation of paddle is
slow down and turns on the fluorescence. As a molecule-sized rotor, the fluorescent rotor can
be applied in cellular and even subcellular level and provide more detail physical information
7

of cellular media change between normal and irregular conditions.
The mitochondrion is not only widely known as cellular energy factory to produce ATP and
regulate cellular metabolism but plays a central role to the Ca2+ induced apoptotic59-61 and
necrotic cell death62-64 as well. Among many mitochondrial related disease and pathological
changes, from genetic Friedreich’s ataxia65-68 and Wilson’s disease69,70 to speared obesity and
diabetes,71-80 and ischemia/ reperfusion damage81-85 is most direct and serious as the main
etiology of stroke,86,87 myocardial infarction,88,89 ischemic colitis,90,91 failure of organ
transplantation,92-95 etc.
Ischemia, caused by lack of blood and oxygen in the tissue and cells, leads to alterations and
damages the mitochondrial electron transport chain complexes and produces more ROS,
depletes ATP, decreases pH value, and changes the permeability of both mitochondrial outer
and inner membrane and decreases the efficiency of the antioxidant.96 Reperfusion increases
the significant amount of ROS further, and damages proteins, lipids, and DNA, which lead to
further impairment of mitochondrial function and cell death.97,98 The mitochondrial matrix is
one of the most crowd and viscous place in the cell, which contains a highly concentrated
mixture of hundreds of enzymes, including mitochondrial ribosomes, tRNA, several copies of
the mitochondrial DNA genome, pyruvate, and fatty acids, and metabolic intermediate related
with the tricarboxylic circle.40,44 However, the relationship between the mitochondrial injury
and mitochondrial viscosity is large unknown. Therefore, mitochondrial targeting fluorescence
probes capable of detection of mitochondrial viscosity change in ischemia/ reperfusion damage
is highly valuable for the study of damage mechanism and pathology.
8

2.2 Design of mitochondrial targeting fluorescence viscosity probe

Silica Rhodamine(SiRhB), pioneered by Nagano and Urano, is a near-infrared to far-red
fluorophore with excellent photophysical properties and biocompatible characteristics.5,99-105
It comprises 9-silaanthracene fluorophore moiety and a stereo hindered aromatic ring at 10position linking by a single C-C bond. To obtain a high fluorescence quantum yield, a hindered
aromatic ring is usually needed. At the same time, the electron density of aromatic ring at 10position of SiRhB has been proven to play a key role in manipulating the fluorescence behavior.
Inspired by the observation, we envisioned that if a rotatable aromatic ring at 10-position was
used, a new bright long wavelength fluorescence rotor could be produced, and its fluorescence
behavior could be regulated by the rotation of the rotatable aromatic ring, which could be used
to detect viscosity change (Scheme 2.1).
Scheme 2.1. Design of viscosity sensors based on SiRhB fluorescence rotor.
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2.3 Synthesis of fluorescence viscosity probes
A series of SiRhBs were synthesized by nucleophilic addition of a freshly prepared
aromatically lithium solution in THF at −78 °C to the reported key intermediate Si ketone, in
mild to good yields (Scheme 2.2).5,103,106 Because a series of aromatically lithium
intermediates can be obtained by lithium-halogen exchange for phenyl derivative and lithiumhydrogen exchange for thiophene, thiazole and benzothiazole, the probes can be accessed with
high overall yields, such as benzothiopheneSiRhB obtained with 34% from 3-bromoaniline in
5 steps.
Scheme 2.2. Synthesis of SiRhB fluorescence rotors.

2.4 Fluorescence property of viscosity probes
At first, four free rotatable SiRhB molecules were synthesized with different substituents
at the para-position, and provide a variety of oxidation potentials. The oxidation potentials of
benzene moieties increase from anilineSiRhB to trifluorotolueneSiRhB. In the case of
anilineSiRhB, whose oxidation potential is 0.7 eV, the fluorescence was totally quenched in
inviscid liquid, water-methanol mixture (0.7 cP). As expected, the fluorescence was gradually
recovered when the viscosity is increased from 0.7 cP to 360 cP. No fluorescence intensity
10

changes of the hindered molecules, methylbenzeneSiRhB and methoxylbenzeneSiRhB, were
observed indicating no correlation with viscosity. This proved that the fluorescence recovery
of the free rotatable anilineSiRhB is due to form a fluorescent rotor (Fig 2.1).
To make the SiRhB fluorescent rotor more sensitive to viscosity, the enhancing hindrance of
rotation need be reduced. As five-member aromatic ring provides less hindrance and lower
oxidation potential than the benzene ring, we synthesized a series of five-member ring SiRhB,
accordingly. To our delight, all of them show better performance of viscosity response than
anilineSiRhB. Their viscosity-dependent fluorescence intensity is described by the FörsterHoffmann equation (Eq. 2.1). Calculated by the Förster-Hoffmann equation, the data points of
rotor emission intensity over solvent viscosity, drawn in a double-logarithmic scale, lied on a
straight line with a slope of x (Fig 2.1). For benzothiazoleSiRhB, the slope of x is up to 0.6,
which is higher than some other viscosity probes and makes our probe more sensitive to the
viscosity change. It should be noticed that the five-member rings are incorporated into these
probes, which make the fluorescence emission wavelength continually bathochromically shift,
and longer than 700 nm into the far-red range, an important feature for deep tissue imaging.

log I = C + xlogη
I: Fluorescence emission intensity
η: Solvent Viscosity
x: dye dependent constant
C: concentration and temperature constant

Eq. 2.1. Förster-Hoffmann equation
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Figure 2.1. Fluorescence study of SiRhBs toward viscosity (a) The responses of six-member ring substituted
SiRhBs towards viscosity. (b) The chemical structures of SiRhBs. (c) The responses of five-member ring
substituted SiRhBs towards viscosity comparing with anilineSiRhB. (d) The responses of five-member ring
substituted SiRhBs towards viscosity comparing with anilineSiRhB in a double-logarithmic scale. 10 μM SiRhB
is dissolved in 10 mM HEPES buffer containing 0.1 % DMSO. After 3 min, the emission intensity of
fluorescence is collected. The emission wavelength is shown on the figure for each SiRhB specifically, and
excited wavelength is 20 nm less than emission wavelength shown on the figure specifically. The standard
solutions of viscosity are mixture of MeOH, water and glycerol with different ratio according the reference.

2.4. Determination of factors affecting fluorescence performance
Having demonstrated good response towards viscosity of these probes, the selectivity of
the probes for various media was examined. Firstly, a series of different solvents were screened
12

such as water, methanol, acetone, toluene, and glycerol (Figure 2.2). These solvents have
different polarities and viscosities. Due to the difference of electrical dipole moment of the
twisted excited state with the one of planar ground state, many fluorescence rotors have been
reported with interference from polarity. We found that our probes were shown low
450
water
methanol
ethanol
DMSO
acetonitril
acetone
DCM
chloroform
toluene
glycerol

Fluorescence Intensity (a.u.)

400
350
300
250
200
150
100
50
0

thiopheneSiRhB

phenothiazoleSiRhB

phenothiopheneSiRhB

anilineSiRhB

Figure 2.2. Viscosity selectivity studies of SiRhB fluorescent rotors in the various solvents. 10 μM SiRhB is dissolved
in various solvents containing 0.1 % DMSO. After 3 min, the emission intensity of fluorescence is collected.

fluorescence in the inviscid solvent, no matter highly polar water or nonpolar toluene. The only
responded solvent is glycerol with its high viscosity in contrast to other solvents.
The pH effect was studied next. All five-member ring probes have no significant change
of fluorescence intensity from pH 1 to pH 10, a range is broad enough for biological studies.
It is noted that due to the protonation of the amino group on the aniline moiety, the
anilineSiRhB showed fluorescence enhancement when pH is lower to 4 (Figure 2.3). The data
clearly showed that the pH effect is minimal.
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Figure 2.3. Selectivity studies of SiRhB with the pH values of solvent. 10 μM SiRhB is dissolved in various
the aqueous solutions with various pH containing 0.1 % DMSO. After 3 min, the emission intensity of
fluorescence is collected. The solutions of pH 0-4 are made by HCl solution, the solution of pH 5-9 are made
by 10 mM phosphate buffer, and the solution of pH 10-14 are made by NaOH solution.

Finally, the interference from a variety of biological related species was tested, including
thiols cysteine and glutathione, cations Ca(II), Cu(II), Fe(III), Mg(II), Zn(II), and ROS
species H2O2, HClO and superoxide. It was found that none of them interfered with the
detection (Fig 2.4).
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Figure 2.4. Selectivity studies of benzothiopheneSiRhB with biologically relevant species. To the
benzothiopheneSiRhB 10 μM in 10 mM HEPES buffer containing 0.1% of DMSO, was added 50 μM biologically
relevant species. The emission intensity was collected 3 min after addition. The excited wavelength is 690 nm, and the
emission wavelength is 710 nm.

The above results clearly showed that the fluorescence intensity of our probe has little
correlation with other micro-environmental changes such as polarity, pH value and ion the
concentration of the solution, but is the function of the viscosity of the solution which fits the
Förster-Hoffmann equation. The probe displayed excellent sensitivity and selectivity over
other biological species.
2.5. Fluorescence performance in cells
Encouraged by the studies, the probes were applied in live cells to test their intracellular
behaviors, including viscosity sensitivity, member penetration, distribution, and toxicity.
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After incubating the probe benzothiopheneSiRhB with HeLa and B35 cells for 1 min, a
dramatic drop of fluorescence intensity of buffer solution was observed. It appears that the
probe facilely got into the cell. For example, after incubation 3 × 105 ml-1 HeLa cell with 5.0
μM benzothiopheneSiRhB at 22.5 °C, 74% of probe accumulated inside the cell (Figure 2.5).
As incubation time (1 min) was extremely fast than most of the other probes, we tried to
understand its transport pathway. Because the low temperature slows active transport,107,108 the
cells were incubated in normal condition except the temperature dropped to 4 °C. The result
showed although the accumulation goes slower, it still had 41% probe molecules to pass into
the cell. Based on this, it is suggested the probe penetrates through the cell membrane by
passive diffusion instead of active transport. This efficient membrane penetration ability
provides an important benefit for cellular detection and imaging.
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The intracellular distribution of the probes was studied first. Colocalization obtained by
using a confocal laser microscope with MitoTracker green and LysoTracker blue are shown in
panels (A−C) and (D−F) in Fig 2.6 and 2.7, respectively. ThiopheneSiRhB and
benzothiopheneSiRhB

mainly

matched

with

MitoTracker

green,

indicating

both

thiopheneSiRhB and benzothiopheneSiRhB are located in mitochondria. As these molecules
without typical mitochondria directing moiety, such as triphenylphosphonium, we believe the
positive charged lipophilic SiRhB structure serves as a directing moiety targeting mitochondria,
similar to Rhodamine 6G and Rhodamine 123. To our surprise, in contrast with

Normalized Fluorescence Intensity (%)

thiopheneSiRhB and benzothiopheneSiRhB, benzothiazoleSiRhB showed completely
120
100
80

***
***

60
40

***

***

20
0

PBS

hela B35
22.5 oC

hela B35
4 oC

Figure 2.5. Fluorescence study of permeability for cell membrane of phenothiopheneSiRhB. To suspended cells in
different temperatures were added 5 μM phenothiopheneSiRhB. The suspension was centrifuged to remove cell after 1
min. Up layer solution was obtained to test the fluorescence with Ex. 650 nm and Em.700 nm. The photo was obtained
after incubating at 22.5 oC for 1 min and then centrifuge. (Left) PBS control, (Middle) HeLa cell 3 × 105 ml-1, (Right)
B35 cell 1 × 106 ml-1.
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different subcellular distribution, supported by the colocation imaging with lysosome stain.
Unlike most reported lysosome locating probe, benzothiazoleSiRhB does not affect by pH.
Although the reason for the specific subcellular distribution of benzothiazoleSiRhB is still
unknown, our probes are useful for the measurement of the viscosity of important cellular
organelles, mitochondria and lysosome, by simply changing aromatic group.
In order to validate cellular viscosity response of our probe, fluorescence microscope
images were acquired with nystatin as inducer for viscosity enhancement, which has been
proven as an ionophore to induce mitochondrial malfunction and viscosity enhancement
caused by structural changes or swelling of mitochondria.44 The Movie S2.1 clearly showed
after adding nystatin (10 μM) to stained HeLa cell in situ, the fluorescence intensity gradually
increased, which clearly validated our probes responsive to viscosity.
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Figure 2.6. Confocal laser fluorescence microscopic images of HeLa cells treated with 1 and Mito-tracker green or
Lyso-tracker Blue (A) and (D) Fluorescence imaging of phenothiopheneSiRhB in HeLa cells, collected in cys5
channel (B) Fluorescent image of Mito-Tracker Green in GFP channel (C) Merged image of A and B. (E) Fluorescent
image of Lyso-tracker Blue collected by DIPA channel. (F) Merged image of (D) and (E).

Figure 2.7. Confocal laser fluorescence microscopic images of HeLa cells treated with 1 and Mito-tracker green
or Lyso-tracker Blue (A) and （D） Fluorescence imaging of phenothiazoleSiRhB in HeLa cells, collected in
cys5 channel(B) Fluorescent image of Mito-Tracker Green in GFP channel(C) Merged image of A and B. (E)
Fluorescent image of Lyso-tracker Blue collected by DIPA channel. (F) Merged image of (D) and (E).
19

The cytotoxicity of these probes is acceptable for biological studies (Fig. 2.8). An MTT
experiment showed that >95% of HeLa cells survived after 30 min (5 μM probes). After 1 h,
the cell viability remained at ∼87% for benzothiopheneSiRhB and benzothiazoleSiRhB, and
60% for thiopheneSiRhB, respectively. Although longer than 1h or high concentration than 5
μM probes will show significant cytotoxicity, it has little cell viability loss for the cellular
experiment studies with incubation with 5 μM probes for 3 min).

thiopheneSiRhB
phenothiopheneSiRhB
phenothiazoleSiRhB

120

Cell Viability (%)

100
80
60
40
20
0

None

1.0 μM

2.5 μM 5.0 μM
30 min

7.5 μM

10 μM

Figure 2.8. Cytotoxicity of B35 by MTT assays. The varying concentrations of SiRhB were incubated with B35 cell
for 30 min, after removal of culture solution, MTT was added and the assays incubated 2 h.

2.6. Study of viscosity with the probe in cellular ischemia/reperfusion model

To demonstrate the practical application potential of these probes, we built disease models
to test organelle viscosity. Ischemia/reperfusion, which is believed to cause serious damage of
20

mitochondria, is a disease induced by lack of blood and oxygen in the tissue and cells, and
further cascade the change of respiratory-related pathway, produces more ROS, deplete ATP,
decrease pH value, change permeability and damages proteins, lipids and DNA of
mitochondria. These events may induce viscosity change of mitochondria. To test the
hypothesis, the probe phenothiopheneSiRhB was applied to oxygen-glucose deprivation
ischemic model (OGD) in B35 neuroblastoma cells and the corresponding model of
reperfusion of oxygen and glucose (Fig. 2.9). The results showed after OGD, the fluorescence
of the cell was about 14% stronger than the normal control cell, which indicated the viscosity
of mitochondria in the ischemic cell is increased. After reperfusion, the fluorescence of the cell
was similar as OGD model, and the viscosity remained unchanged. In order to further elucidate
its mechanism, we fed various species to the model cell to mimic mitochondria damage or
recovery of ischemia/reperfusion damage. These substances are Zn(II) as an inhibitor of
cellular energy production; Fe(II) and Fe(III) catalyzing ROS related Fenton reaction; ROS
species H2O2, HClO and superoxide induced by K2O; cyanide ion and azide ion as inhibitors
of cytochrome C; and protein denaturation inducer Pb(II). The normal cell, OGD model and
reperfusion model responded differently. Zn(II) is prone to increase the viscosity for all three
models. The dramatic enhancement was observed for Zn(II) feeding. After the addition of 100
μM Zn(II) to the normal cell, the fluorescence is increased by more than 40% in fluorescence
intensity, indicating viscosity increased dramatically. In the OGD and the reperfusion model,
the enhancements of fluorescence are 24% and 30% respectively after feeding 100 μM Zn(II).
Zn(II) played key role in the ischemic induced cell death.109-112 The generally accepted
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mechanism included five parts, 1) inhibition of glycolysis, 2) inhibition of tricarboxylic acid
cycle (TCAC), 3) inhibition of the electron transport chain (ETC), 4) generation of ROS, 5)
change of mitochondrial permeability (MPT), and inducing nonselective exchange of species
of up to 1.5 kDa between mitochondria and cytosol. The OGD model, inhibited all three steps
of intracellular respiration, glycolysis, TCAC and ETC, had no significant perturbation for the
viscosity. And at same time, cyanide and azide, as inhibitors of cytochrome C in the ETC,
showed little response for all model. The results indicated the mitochondria viscosity change
has no clear relationship with any of respiration steps, glycolysis, TCAC or ETC. Fe(II) and
Fe(III), the inducer of ROS related Fenton reaction, increasing mitochondria viscosities in the
OGD and reperfusion groups, indicated ROS was a possible reason for mitochondria viscosity
increase. But it was not the only condition, since 1) Fe(II) and Fe(III) have no response in
normal group; 2) feeding of external ROS species H2O2, HClO and superoxide without show
significant change of mitochondrial viscosity. The change of MPT may be the second condition.
Due to inducing both increase of ROS and the change of MPT, Zn(II) enabled to enhance
mitochondrial viscosity in any condition. Since the changes of MPT was presented in the OGD
or reperfusion model cells, the mitochondrial viscosities for OGD and reperfusion groups were
sensitive to Fe(II) and Fe(III), ROS inducer. It indicates the homeostasis of iron in the OGD or
reperfusion model are impaired by the change of MPT.
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Figure 2.9. Viscosity study of B35 OGD/Reperfusion model. OGD model was established by treating B35 cell with low
oxygen and no glucose condition for 1.5 h. Reperfusion model was obtained by OGD model recover glucose and oxygen
for 30 min. Removal of media, cell counting, tuning cell concentration to 1×106 ml-1, centrifuging and washing by PBS,
tuning cell concentration to 2×106 ml-1 again, adding cell suspension and detecting species into 96 wells plate (final cell
concentration 1×106 ml-1), detecting fluorescence (Ex. 650 nm and Em. 700 nm)

Finally, we applied our probe to stain striatal of rat brain in middle cerebral artery occlusion
(MCAO) slide (Fig 2.10) and hemorrhagic slide (Fig 2.11) Dramatic enhancement of the
fluorescence from damaged tissues in both model contrast with normal tissues shows the
capability of our probe to applied in diagnosis.
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Figure 2.10. Fluorescent images of mitochondria viscosity in rat’s ischemic brain tissue. Brain sections were incubated
with 5.0 μM phenothiopheneSiRhB for 15 min at nonischemic side and at ischemic side. The graph shows the relative
mean fluorescence intensities of the brain section images. (A), (B) and (C) at nonischemic side and (D), (E) and (F) at
ischemic side.
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Figure 2.11. Fluorescent images of mitochondria viscosity in rat’s hemorrhagic brain tissue. Brain sections were
incubated with 5.0 μM phenothiopheneSiRhB for 15 min at nonhemorrhagic side and at hemorrhagic side. The graph
shows the relative mean fluorescence intensities of the brain section images. (A), (B) and (C) at nonhemorrhagic side and
(D), (E) and (F) at hemorrhagic side.
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2.7. Conclusion

In conclusion, we have developed new far-red sensitive and selective fluorescent probes for
the detection of viscosity level using fluorescence rotor strategy. Notably, the probes displayed
extremely fast penetration through the cell membrane (within 3 min) and dramatically
concentrated accumulation in the cell. The targeting organelle is tunable from mitochondria to
lysosomes by simply changing aromatic ring moiety. These features allow for the convenient
detection of viscosity in subcellular organelle. Furthermore, we observed the mitochondrial
viscosity change induced by ischemia/ reperfusion damage, and then further studied its
possible mechanism. The probe holds great potential for the investigation of the viscosity in
cellular and animal models.

2.8. Experiment section

General Information: Commercial reagents were used as received unless otherwise stated.
Merck 60 silica gel was used for chromatography, and Whatman silica gel plates with
fluorescence F254 were used for thin-layer chromatography (TLC) analysis.
Spectroscopic Materials and Methods: Fluorescence emission spectra were obtained on a
SHIMADZU spectrofluorophotometer RF-5301pc. The UV absorption spectra were obtained
on a SHIMADZU UV-1800.
1

H and 13C NMR spectra were recorded on Bruker Avance 500 and Bruker tardis (sb300). The

signals in 1H and 13C NMR spectra were referenced to the residual peak of a deuterated solvent.
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Data for 1H are reported as follows: chemical shift (ppm), and multiplicity (s = singlet, d =
doublet, t = triplet, q = quartet, m = multiplet, br = broad). Data for 13C NMR are reported as
ppm.
Cell Culture: All cells were cultured in DMEM medium (Gibco) supplemented with 10% FBS,
2 mM Gluta MAX (Life Technologies), 100 U/mL penicillin (Life Technologies) and 100
μg/mL streptomycin (Life Technologies) at 37 °C in a humidified atmosphere containing 5%
CO2.
Cell viability assay: Cell viability was determined by the MTT assay. Cells (5 × 104/well)
were seeded in a 96-well plate overnight before treatment with the corresponding compound
for designed time. After the exchange the medium to pure DMEM, 20 μl of the MTT solution
(5 mg/ml) was added to each well and incubated at 37 °C for 2 h. The supernatant was removed,
and the insoluble formazan product was dissolved in 100 μl of DMSO. The absorbance of each
culture well was measured with a microplate reader (Molecular Devices, USA) at a wavelength
of 570 nm.
Confocal Fluorescence Images: Confocal fluorescence images were acquired with Zeiss
LSM 800 AiryScan Confocal Microscope. equipped with a 130 W mercury lump, an EMCCD
camera (Hamamatsu Photonics, ImagEM), and a disk scan confocal unit (DSU). Images were
obtained with appropriate filter sets for each dye as follows.
MitoTracker green: GFP filter set (excitation = 457 - 487 nm, emission = 502 - 538 nm).
LysoTracker blue: DAPI filter set (excitation = 350 - 400 nm, emission = 415 - 470 nm)
SiRhodamine: Cy5 filter set (excitation = 610 - 650 nm, emission = 672 - 712 nm)
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For all imaging experiments, DMEM without phenol red was used.
After incubation for 30 min at 37 °C, the cells were washed with DMEM (× 1), and then imaged.
Analysis was performed with ImageJ.
OGD model: The cells were cultured in the normal condition in the six-well plate overnight.
OGD model was established by treating B35 cell with low oxygen and no glucose condition
for 1.5 h in the hypoxia chamber at 37 °C. Reperfusion model was obtained by OGD model
recover glucose and oxygen for 30 min. After removal of media, lysis and cell counting, tuning
cell concentration to 1 × 106 ml-1, centrifuging and washing by PBS, tuning cell concentration
to 2 × 106 ml-1 again, adding cell suspension and detecting species into 96 wells plate (final
cell concentration 1 × 106 ml-1), detecting fluorescence (λex: 650 nm and λem: 700 nm).
Animal Model of Focal Cerebral Ischemia: The Laboratory Animal Care and Use
Committee at the University of New Mexico approved all experimental protocols. Male
Sprague−Dawley rats (Charles River) weighing 290 to 320 g were subjected to 1.5 h of MCAO
followed by 5 min of reperfusion using the intraluminal suture occlusion model, as we
described previously. Rats were anesthetized with 2% isoflurane during surgical procedures.
Prior to reperfusion, all rats included in this study displayed neurologic deficit typical of
MCAO, circling to the left (nonischemic side).
At the end of reperfusion, the rats were transcardially perfused with ice-cold PBS and 4%
paraformaldehyde, and then the brain was quickly taken out. The brain tissue was frozen in
optimal cutting temperature (OCT) solution for cryosectioning. A set of 20-μm-thick brain
sections was generated from the selected brain region (+1.5 to −3.5 mm relative to the bregma).
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After washing with PBS three times, the sections were incubated with 0.3% Triton X-100.
Then, the probe was added onto the sections. Following by 15 min incubation and thorough
washing, each section was photographed under the Olympus IX-81 microscope with Stereo
Investigator software (Olympus, Optical Co. Ltd., Japan).
Synthesis of Probes

Bis(2-bromo-4-N,N-dimethylaminophenyl)methane
To 3-bromoaniline (16 g, 93.01mmol) in sulfuric acid (56 mL) and THF 250ml,
formaldehyde 37% solution (27.78 ml, 279.0 mmol) was added, and then NaBH4 (14.07g,
372mmol) was added in an hour. the mixture was stirred another 30min. formaldehyde 37%
solution (9.26 ml, 93.0 mmol) was added. The mixture was stirred at 70

℃

overnight. After

cooling, saturated NaHCO3 was added, and the whole was extracted with CH2Cl2. The organic
layer was dried over Na2SO4 and evaporated. Recrystallization by anhydrous ethanol provided
pure bis(2-bromo-4-N,N-dimethylaminophenyl)methane as a white solid (12.9 g, 67 % yield).
1

H NMR (300 MHz, CDCl3): δ (ppm) 2.91 (s, 12H), 4.03 (s, 2H), 6.59 (dd, 2H, J = 8.6 Hz,

2.4 Hz), 6.87 (d, 2H, J = 8.6 Hz), 6.96 (d, 2H, J = 2.6 Hz). 13C NMR (75.5 MHz, CDCl3): δ
(ppm) 40.0, 40.6, 112.0, 116.4, 125.8, 127.2, 130.9, 150.2.
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Si-xanthone
To

a

flame-dried

flask

flushed

with

argon,

bis(2-bromo-4-N,N-

dimethylaminophenyl)methane (4.12g, 10 mmol) and anhydrous THF (50 mL) were added.
The solution was cooled to – 78 °C, 2.0M n-BuLi (40 mmol) was added, and the mixture was
stirred for 30 min. At the same temperature, SiMe2Cl2 (10 mmol) was slowly added and then
the mixture was warmed to room temperature. The reaction was quenched by addition of 2 N
HCl and stirring was continued at r.t. for 10 min. Saturated NaHCO3 was added, and the whole
was extracted with CH2Cl2. The organic layer was dried over Na2SO4 and evaporated. The
residue was dissolved in acetone (100 mL), following the addition of a sufficient amount of
KMnO4. The mixture was stirred overnight, and the solvent was evaporated again. The
resulting residue was purified by column chromatography to give pure Si-xanthone as a yellow
solid. (1.59 g, 4.9 mmol, 49 % yield). 1H NMR (300 MHz, CDCl3): δ (ppm) 0.47 (s, 6H),
3.09(s, 12H), 6.79 (d, 2H, J = 2.7 Hz), 6.84 (dd, 2H, J = 9.0 Hz, 3.0 Hz), 8.39 (d, 2H, J = 9.0
Hz). 13C NMR (75.5 MHz, CDCl3): δ (ppm) −0.8, 40.2, 113.4, 114.5, 129.9, 131.8, 140.7,
151.7, 185.5.
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General Procedure for the Syntheses of Si General Procedure for the Syntheses of SiRhodamines.

To a flame-dried flask flushed with argon, aromatic derivative (0.50 mmol) and anhydrous
THF (5 mL) were added. The solution was cooled to – 78 °C, 2.0 M n-BuLi (0.50 mmol) was
added, and the mixture was stirred for 30 min. At the same temperature, Si-xanthone (10.0 mg,
0.0308 mmol) dissolved in anhydrous THF (5 mL) was slowly added, and the mixture was
warmed to r.t. then stirred for 2 h. The reaction was quenched by addition of 2 N HCl and the
mixture was stirred at r.t. for 10 min. Saturated NaHCO3 was added, and the whole was
extracted with CH2Cl2. The organic layer was dried over Na2SO4 and evaporated. The resulting
residue was purified by column chromatography to give pure Si-Rodamine as a blue to green
solid.

ThiopheneSiRhB
(yield 60%); green solid; 1H NMR (300MHz, CDCl3): δ (ppm) 0.59 (s, 6H), 3.42 (s, 12H),
6.70 (dd, 2H, J = 9.6 Hz, 3.0 Hz), 7.08 (dd, J = 3.3 Hz, 1.2 Hz) 7.18 (m, 3H), 7.35 (d, 2H, J =
9.6 Hz), 7.59 (d, 1H, J = 1.2 Hz), 13C NMR (75.5 MHz, CDCl3): δ (ppm) -0.6, 41.3, 114.0,
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121.0, 127.0, 128.9, 130.4, 138.7, 142.0, 148.0, 154.1, 161.6

PhenothiopheneSiRhB
(yield 76%); green solid; 1H NMR (300MHz, CDCl3): δ (ppm) 0.63(s, 6H), 3.42 (s, 12H), 6.65
(dd, 2H, J = 9.6 Hz, 2.7 Hz), 7.23 (d, J = 3.0 Hz) 7.34 (s, 1H), 7.48 (m, 4H), 7.87 (m, 2H), 13C
NMR (75.5 MHz, CDCl3): δ (ppm) -0.5, 41.4,114.1, 121.4, 122.0, 124.2, 125.5, 125.6, 127.2,
128.5,139.1,139.2,140.6,141.9,148.2,154.3,160.9.

PhenothiazoleSiRhB
(yield 35%); green solid; 1H NMR (300MHz, CDCl3): δ (ppm) 0.63(s, 6H), 3.42 (s, 12H), 6.66
(dd, 2H, J = 9.6 Hz, 2.4 Hz), 7.14 (d, 2H, J = 9.6 Hz) 7.27 (d, 1H, J = 2.4 Hz), 7.58 (m, 2H),
7.87 (m, 2H), 8.01 (d, 1H, J= 8.1 Hz), 8.17 (d, 1H, J= 8.1 Hz) (d, 1H), 13C NMR (75.5 MHz,
CDCl3): δ (ppm) -0.8, 41.1, 113.9, 121.1, 121.7, 123.9, 125.1, 125.3, 126.9,
128.1,138.8,140.2,141.6,147.7,153.9, 160.6.
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anilineSiRhB
The reaction started from N-(4-bromophenyl)-1,1,1-trimethyl-N-(trimethylsilyl)silanamine.
And the protecting groups were automatically removed when HCl was added to the reaction
for quench. (yield 71%); blue solid; 1H NMR (300MHz, CDCl3): δ (ppm) 0.54 (s, 6H), 3.34
(s, 12H), 6.60 (dd, 2H, J = 9.6 Hz, 2.7 Hz), 6.84 (d, 2H, J = 8.4 Hz), 6.93 (d, 2H, J = 8.4 Hz),
7.09 (d, 2H, J = 3.7 Hz), 7.37 (d, 2H, J = 9.6 Hz), 13C NMR (75.5 MHz, CDCl3): δ (ppm) -0.7,
40.1, 113.3, 114.1, 120.1, 127.2,128.5,131.4,143.1,148.1,149.1,153.8,172.6.
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Figure S2.1 Fluorescence spectrum for different viscosity. The viscos solution was mixture of water, methanol and
glycerol, the viscosities of the solutions were tested by Ubbelohde viscometer.
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Chapter 3 “Off−On” Fluorescence Probe Enabling Detection of
Mitochondrial Labile Fe(II) and Its Application for the Study of
Chemical Induced Fe(II) Flux in Ischemic and Hemorrhagic Stoke
Abstract

Iron, the most abundant and essential transition metal in the human body, participates several
indispensable biological processes, especially ROS and NOS engaged redox. However, the
subcellular labile iron information and its relationship with dysfunction or disease remain
elusive due to the limitation of detecting methods. In this study, a new mitochondrial specific
Fe(II) probe was designed and synthesized based on the Fe(II) mediated cleavage of N-O bond.
The probe exhibited a sensitive and selective turn-on response against Fe(II) in chemical
system and the live cell. It is capable of detection of the endogenous labile iron pools in both
live-cell fluorescence imaging and flow cytometry. The studies using the probe reveals the
fluctuation of Fe(II) concentration in the zinc or nystatin induced mitochondria respiratory
failure, and the increase of Fe(II) in OGD/reperfusion model are observed.
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3.1. Introduction

Iron, the most abundant and essential transition metal in the human body, participates
several indispensable biological processes from oxygen delivery,113,114 electron transport chain
(ETC),115,116 gene expression,117 enzymatic activities,118 cellular growth,119 to reactive oxygen
species (ROS)119-122 and reactive nitrogen species (NOS)123,124 producing and cleaning up. The
potent redox capability of protein chelated iron is utilized for a series of central roles in normal
biological events. However, the potent redox capability of labile iron, mainly Fe(II), induces
Fenton reaction and enhances the activity of ROS,125 which damages intracellular normal
protein, lipid or DNA, and further triggers cell death through direct or indirect cellular
signaling.126 The dysregulation of iron homeostasis has a close relationship with many diseases,
such

as

iron-deficiency

anemia,127

liver

damage,128,129

cardiac

dysfunction,130-132

neurodegenerative diseases,133-135 diabetes,136-138 and cancer139,140. Unfortunately, although
labile iron attracts the most attention as primary transition metal signaling,141 the subcellular
labile iron information and its relationship with dysfunction or disease are still unclear due to
the limitation of detecting methods.
The fluorescent probe provides the subcellular spatial, temporal and elemental valent
information with high sensitivity, low toxicity, easy operation, and visualization
capability.142,143 Challenged by 1) specification of two different oxidation and spin states
Fe(II)/ Fe(III); 2) differentiation from other first line divalent transition metals, especially
Co(II), Cu(I), and Ni(II); 3) disturbing by other reducing reagent, such as thiol, Vc or Cu(I);144
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4) fluorescence quenching from coordination of paramagnetic iron;145 Fe(II) selective
fluorescent off-on probes are still very limited.10,146-150 Only a handful of probes were reported
recently for biological imaging and labile Fe(II) concentration detection. Chang and coworkers disclosed a type Fe(II) probe based on intramolecular ligand bonded Fe(II) and its
induced C-O bond cleavage via oxygen participated Fenton reaction.149,150 Lately, the same
group extended this Fe(II) specific Fenton reaction related chemistry to a new type of probe
with 1,2,4-trioxolane ring structure which had specific reactivity for Fe(II) dependent reduction
of peroxide bond.10 Nagasawa also reported a type of Fe(II) probe based on N-oxide chemistry
and recently they successfully detected the intracellular labile iron increase in hypoxic tumor
cells.151
The mitochondrion is a double-membrane-bound organelle found in almost all eukaryotic
organisms. The mitochondrion is well known for its key role in energy transduction, and also
a focal point of iron metabolism.152,153 Iron is needed for heme and iron-sulfur cluster (ISC)containing proteins involved in electron transport and oxidative phosphorylation. It makes that
mitochondria are crowded with iron-containing protein, from functional protein hemoglobin
and ISC, iron storage protein mitochondria transferrin and frataxin, to iron transporter DMT1
and Mitoferrin. As such, mitochondria are “hubs” of cellular iron trafficking. At the same time,
mitochondrion is one of the organelles with most enriched ROS,154 NOS,155 which are
considered as highly toxic and fatal for the cell. Moreover, labile iron can boost the production
and aggressiveness of ROS and NOS through Fenton reaction, Therefore, under normal
physiological conditions, the iron is carefully regulated in the mitochondria, most of the iron
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is trapped in the iron-binding protein and only limited iron presents in the labile state.
Conversely, the excess of iron, ROS, and damaged mitochondria protein have been found in
the pathologic states, such as in the ischemic states.156 It is hypothesized that the if the ROS
signal is out of the control, ROS will damage the iron contain mitochondria protein, and
enhance the concentration of labile iron, which directly induces the positive feedback of the
ROS concentration and further damage cell or induces programmed cell death. But until now
no one directly detected the hypothesized change of mitochondria labile iron and this Fenton
loop in the living cell. To verify this hypothesis, we need a mitochondrial targeting Fe(II)
probed. But for our knowledge, it’s no reported cellular off-on mitochondrial specific Fe(II)
probe. In this study, we reported a new designed mitochondrial specific Fe(II) probe, and
directly observe the fluctuation of labile iron Fe(II) concentration from zinc or nystatin induced
respiratory failure, and oxygen-glucose depletion and reperfusion model(OGD/reperfusion) at
cell level, and labile Fe(II) enhancement in MCAO and intracerebral hemorrhagic (ICH)
animal model.
3.2. Design and synthesis of fluorescent probes of Fe(II)
In our previous work, we reported nalphthalimide type N-aryl-O-acylhydroxylamine to
be useful fluorescent probes for detecting labile Fe(II) in living cells by exploiting N-O bond
chemistry,29 whose fluorescence off-on is induced by internal charge transfer effect (ICT) due
to electron density enhancement from hydroxylamine group to the amine group (Scheme 3.1).
However, its wavelength range is limited to the green region, Cu(I) and ascorbate significantly
interrupt detection of Fe(II). Moreover, it cannot target desired cellular organelle, mitochondria.
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After deliberating our N-O bond chemistry, we designed and synthesized a new Rhodamine
type Fe(II) probe. Rhodamine type fluorogenic probes were widely used in biology and
biochemistry because it’s excellent fluorogenic character and relatively low toxicity. It is
demonstrated the formation of the turn-off state of dark Rhodamine fluorogenic probe by the
isolation of the amine group from the π-conjugate system of rhodamine by electron
withdrawing groups, such as acyl or N-oxide. It not only reduces the fluorescence of the
molecular by ICT effect through the loss of lone pair electrons of amine group same as
nalphthalimide, but primarily locks the Rhodamine molecule in the colorless spirolactone state
and reduce absorption as well. Furthermore, compare with previous nalphthalimide type probe,
the aromatic system of RhB has higher electron density and provides higher reactivity for the
cleavage of N-O bind.
It is known that many Rhodamine type molecules, such as Rhodamine 123 and Rhodamine
B are reported to target mitochondria well since triarylmethane moiety is a lipophilic cation.
Taking advantage of the small molecular weight difference from Rhodamine type fluorophore
to its hydroxylamine derivative, the mitochondria targeting character could be explored. We
found the original RhB hydroxylamine without O-acyl modification showed satisfying
sensitivity and selectivity, although its O-acyl derivative is too sensitive and unstable which
discompose in hours in buffer. Through structure modification, particularly the detection
moiety, a new probe is developed and shows 1) lower interference from Cu(I) and Vc, 2) longer
excitation and emission wavelength, 3) low cytotoxicity and 4) more importantly, excellent
intracellular distribution and mainly targeting mitochondria, the center of intracellular iron
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metabolism (Scheme 3.1).
Scheme 3.1. Design of Fe(II) selective fluorescent probe based on Fe(II) induced hydroxylamine cleavage.

Scheme 3.2. Synthetic route of Probe 1.

The designed Probe 1 is conveniently prepared through an F-C condensation between mnitrophenol and 2-(4-(diethylamino)benzoyl)benzoic acid and then reducing nitro group to
hydroxylamine via Zn/ammonium chloride system. (Scheme 3.2) it was fully characterized by
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1

H and 13C NMR.

3.3. Photophysical properties and fluorescence response of the probe
With the compound in hand, we carried out fluorescent property studies in the pH 7.4
HEPES buffer solution. It was no fluorescent and colorless. Nonetheless, upon addition 1 μM
of Fe(II) fluorescence, intensity significantly increased with 50 μM of Fe(II). Notable
fluorescence enhancement (>10-fold) was observed within 10 min at 554 nm, and slightly pink
color was observed, which can also be seen by nude eyes or UV-Vis spectrum (Fig. 3.1 and
3.2). These results proved our hypothesis that hydroxylamine group locks the probe molecule
in the spirocyclic noncolor form, and the deep color open form will be induced by reduction
from hydroxylamine to amine in the presence of Fe(II). The formation of its amine derivative
was confirmed by comparison with a synthetic pure compound and emission spectra. The
stability of this probe in a buffer solution, a very limited fluorescence increase was observed
over 1 h in the dark or continuous illumination under 500 nm light, respectively. pH effect was
also investigated, it shows 3 folds of fluorescent enhancement in the acidic condition (pH <=
3), which can be attributed to the spirolactone cycle state change from close form to open form,
this phenomenon also can be verified by the significantly weak absorption in visible region on
the UV-Vis spectra. The spirolactone causes no absorption and emission and thus has a low
background signal due to loss of p-conjugation, resulting in effective off/on contrast. Since the
pH value of the cell is mainly from 4.5 to 8, the fluorescence stability range of pH value (from
4-12) is enough for the biological application.
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Figure 3.1. Sensitivity study of Probe 1 toward Fe(II). To 5.0 μM Probe 1 in 50 mM HEPES, pH 7.4 (containing 0.1%
DMSO), was added Fe(II) at 0, 1.0, 3.0, 5.0, 10.0, 20.0, 30.0, 40.0, 50.0 and 60.0 μM. The emission intensity was collected
at 554 nm. The excitation is at 500 nm, and the slit was set at 5/5.

Figure 3.2. Response rate study of Probe 1 toward Fe(II). To 5.0 μM Probe 1 in 50 mM HEPES, pH 7.4 (containing
0.1% DMSO), was added 50.0 μM Fe(II). The emission intensity was collected at 554 nm. The excitation is at 500 nm,
and the slit was set at 5/5.

The fluorescent turn-on response of Probe 1 is selective for Fe(II) not only overabundant
cellular reductant spices, like cysteine, glutathione, sulfide ion, NADH and ascorbic acid, but
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also over intracellular ROS species, H2O2, NaClO and superoxide ion (Figure 3.3). It also
exhibits high selectivity over other biologically relevant 3d metal ions like Cu(I), Cu(II), and
Zn(II) (Figure 3.4). It should be noticed that ascorbic acid and Cu(II) has minimal effect on
Probe 1, which is one of the main problems for our previous nalphthalide probe.
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Figure 3.3. Selectivity studies of Probe 1 with biologically relevant reductive species and biologically relevant ROS
species. To 5.0 μM Probe 1 in 50.0 mM HEPES, pH 7.4 (containing 0.1% DMSO), was added 50 μM of Fe(II), 200 μM
of Na2S, 200 μM of Na2S2O3, 200 μM of Na2SO3, 200 μM of cysteine, 200 μM of GSH, 200 μM of NADH, 200 μM of
Ascorbate, 200 μM H2O2, 200 μM NaClO and 200 μM KO2. The emission intensity was collected 10 min after addition
of different reductive species.
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Figure 3.4. Competition assays of Probe 1 with other biologically relevant metal ions. The bar on the left was 5.0 μM
Probe 1 or 5.0 μM Probe 1 with a specified cation; the right bar was 50 μM Fe(II) in the presence of a specified cation
at 1 mM Na(I), K(I), Ca(II), Mg(II) or 200 μM other 3d metals. The emission was recorded at 554 nm after 10 min
incubation.

3.3. Cellular imaging studies
Toxicity study of Probe 1
The cytotoxicity using HeLa cells was firstly evaluated. It was found that in the low
concentrations (<10 μM) of the probe, it is nontoxic (Figure 3.5). The viability of the cell
decreased slightly if the concentration is higher than 10 μM. However, in our following studies,
the probe concentration was set at 5.0 μM.
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Figure 3.5. The HeLa cell viability of Probe 1. The HeLa cells were treated with indicated concentration of probe for 12, 24
or 36 hr. in DMEM medium. Then the cell viability was measured by MTT method.

Probe 1 was applied for fluorescent imaging of Fe(II) in HeLa cells. Fast response and
bright images were observed when the cells were treated with 5.0 μM Probe 1 for only 15 min
(Fig. 3.6). Furthermore, the same cells were treated with additional100 μM exogenous Fe(II)
in situ, the fluorescent intensity was further increased 30% after 120 s. We also designed a
contrast experiment by treating the HeLa cell with DFO, a clinically used chelating agent for
iron. The fluorescence image was significantly dimmed. Further treating with exogenous Fe(II)
in situ, a reversed ‘S’ curve was obtained from fluorescent intensity of cell image, which can
be explained by intracellular DFO complexed by exogenous Fe(II) in the first minute and
leading to the fluorescent intensity increase. When all DFO was neutralized, the fluorescent
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intensity was fully recovered in the second minute. These studies provide solid evidence that
the probe can detect not only endogenous labile Fe(II), but also responsible for exogenous one

Figure 3.6. a) Fluorescent images of Fe2+ in HeLa cells. Magnification = 10× for images a,b and d,e. (a) HeLa cells were
incubated with 5.0 μM Probe 1 and 200 nM DAPI for 15 min; (b) a was treated with 100 μM Fe2+ for 2 min in situ; (c)
tracking of the fluorescent intensity enhancement from a to b in situ. The image was captured at 30, 60, 90 and 120s after
exogenous Fe2+ was added. The intensity of fluorescence in the red channel for the probe was separated and normalized.
(d) HeLa cells were incubated with 20 μM DFO treated for 15 min and then 5.0 μM Probe 1 and 200 nM DAPI for
another 15 min; (e) d was treated with 100 μM Fe2+ for 2 min in situ; (f) tracking of the fluorescence intensity enhancement
from d to e in situ. The image was captured at 30, 60, 90 and 120s after exogenous Fe2+ was added.

as well. The probe displays very fast response (less than 2 min).
After the cells were treated with Fe(II), the population distribution shifted from a low
fluorescent signal region to a high region in the flow cytometry experiment (Figure 3.7).
However, in the presence of DFO, the signal was suppressed, and the population distribution
shift was reversed. The co-localization experiment between our probe with commercial
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mitochondria targeting probe MitoTracker green (Fig. 3.8) was also conducted. To our delight,
the results showed great match between the image from our probe in the red channel and the
image from MitoTracker green in the green channel. The Pearson’s R value is higher to 0.98.
Since lysosome is also reported with the high concentration of labile Fe(II). We found that
totally different images were obtained from the red channel for our probe comparing with the
image obtained from the blue channel for commercial lysosome targeting probe LysoTracker
blue (Fig. 9) under the similar co-localization experiment conditions. The deviation of the
Pearson’s R value (R = 0.62) far from 1 demonstrated that our probe was not targeting
lysosome. These results suggest that the probe is mitochondria targeting with high cell
permeability, and can detect labile iron pools at endogenous, basal levels with facile and
sensitive response.
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Figure 3.7. Representative flow cytometry histograms of probe labeled HeLa cell. The cells were suspended by 0.4%
trypsin without EDTA. Yellow line: The suspended cells were treated with 5 μM of Probe 1 in PBS for 15 min. Blue
line: The suspended cells were treated with 20 μM DFO 15 min and then with 5 μM of Probe 1 for 15 min in PBS. Green
line: The suspended cells were treated with 100 μM exogenous Fe2+ for 15 min in PBS, after washout, further treated with
5 μM of Probe 1 for 15 min.
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d

Pearson’s R value: 0.98

Figure 3.8. Co-localization studies of Probe 1. Hela cells treated with probe 4 (5 μM) and MitoTracker Green (200 nM)
for 15 min. Magnification = 63× was used for the image. (a) Red channel for Probe 1; (b) Green channel for MitoTracker
Green; (c) combination of red channel and green channel. (d) Geometric view and R value for Pearson’s correlation
coefficient.
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Pearson’s R value: 0.62
Figure 3.9. Co-localization studies of Probe 1. Hela cells treated with probe 4 (5 μM) and LysoTracker blue (75 nM) for
15 min. Magnification = 63× was used for the image. (a) Red channel for Probe 1; (b) Blue channel for LysoTracker
blue; (c) combination of red channel and blue channel. (d) Geometric view and R value for Pearson’s correlation
coefficient.

Study of relationship of Fe(II) and Zu(II) in mitochondria
With the probe in hand, we conducted the study of the labile Fe(II) change in the
dysfunctional state of mitochondria. Zinc has been implicated cell death via mitochondrial
damage,157 which is believed as one of the main reasons for neuron cell death following
ischemia or Alzheimer’s disease.112,158 However, the toxicity mechanism is very complex. Zn
elevated cells show a lower level of glycolysis, the electron transport chain and tricarboxylic
acid cycle, enlarge mitochondrial permeability transition, induce generation more ROS, and
Ca(II) involved cell death. Zinc has been proposed to induce toxicity via directly replace
divalent metal-chelated proteins and/or enlarge mitochondria inner membrane pore following
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with apoptosis induced Ca(II) involved cell death. The roles and relationship of each cation in
mitochondrial damage remains unclear. To further understand their relationship and roles, we
designed the experiment to mimic high Zn(II) condition by exogenous Zn(II) addition. In
control, a parallel experiment to the model of enhancement of nonselective mitochondrial
permeability transition was carried out by addition of exogenous nystatin. The release of Fe(II)
was monitored by the fluorescence enhancement with Probe 1 by feeding of Zn(II) (150.0 μM)
to HeLa cells. Dramatic and quick fluorescent intensity increase was observed (Figure 3.10).
The enhancement is much greater (1.4 fold in 3 min) than the vehicle. A similar result (1.3 fold
in 150 s) treated with nystatin (100.0 μM) was obtained, indicating both Zn(II) and nystatin
may target a similar pathway. It is believed that the toxicity of excess amount of Zn(II) is
mainly induced by the enhancement of nonselective mitochondrial permeability transition and
apoptosis. The studies suggest that labile iron plays a key role in the process. The elevated
level of Fe(II) comes from the damaged iron chelated protein with Zn(II) involvement in the
mitochondria.
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Figure 3.10. a) Fluorescent images of chemical induced labile Fe2+ in HeLa cells. Magnification = 10× for images a,b
and d,e. (a) hela cells were incubated with 5.0 μM Probe 1 and 200 nM DAPI for 15 min; (b) a was treated with 150 μM
Zn2+ for 2 min in situ; (c) tracking of the fluorescent intensity enhancement from a to b in situ. The image was captured
from 30 to 180 s for every 30 s after exogenous Fe2+ was added. The intensity of fluorescence in the red channel for the
probe was separated and normalized. (d) hela cells were incubated with 5.0 μM Probe 1 and 200 nM DAPI for 15 min;
(e) d was treated with 150 μM Zn2+ for 2 min in situ; (f) tracking of the fluorescent intensity enhancement from d to e in
situ. The image was captured from 30 to 180 s for every 30 s after exogenous Fe2+ was added.

3.4. Application of the probe for the study of Fe(II) in cellular ischemia/reperfusion
Tumors display a high rate of glucose uptake and glycolysis. The inhibition of glucose
metabolism could induce programmed death in human tumor cells. Research efforts to develop
therapeutic drugs to target hypoxia-associated tumor cells159 have been ongoing for many years
by targeting HIF1A pathways160,161 to decrease tumor progression and angiogenesis. Thus,
Probe 1 was applied to monitor the fluctuation of mitochondrial labile Fe(II) during cellular
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oxygen/glucose deprivation(OGD)/reperfusion stress response. A flow cytometry study was
conducted to evaluate intracellular fluctuation of mitochondrial labile Fe(II) under OGD (<1%
O2 for 1 h in no glucose media) and reperfusion model further treated with normal oxygen and
4 g/L glucose for 30 min) using Probe 1 as an indicator of the level of mitochondrial labile
Fe(II) (Figure 3.11). As the level of Fe(II) is highly dependent on the concentration of
dissolved oxygen, it was reported that intracellular redox balance between Fe(II)/Fe(III) could
be altered under hypoxic conditions. However, in our condition, the data is short of support for
this hypothesis. The labile Fe(II) in the OGD model with low oxygen concentration did not
display significant difference compared with control study. But the distribution of reperfusion
sample shifted higher from a low fluorescent signal to a high signal region, although this
sample had a normal oxygen concentration. This result indicated the oxidation stress had no
contribution to the increase of labile Fe(II) in the reperfusion. To further verify this, we
synthesized a reported Fe(III) mitochondria target probe to monitor Fe(III) level.162 The
OGD/reperfusion experiment suggests no significant change of Fe(III) concentration (Figure
3.11). Since the enhancement of Fe(II) in mitochondria is not from labile Fe(III) pool, the
possible explanation is reperfusion-induced ROS to trigger further damage and death of the
cells,163,164 which concur with our above Zn2+/nystatin studies.
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3.5. Application of the probe for the study of Fe(II) in ICH and MCAO stroke animal
model

To further demonstrate the potential application of Probe 1, we performed a Fe(II) imaging
Fe(II)

Fe(III)

ROS

Figure 3.11. Representative flow cytometry histograms of probe labeled HeLa cell for OGD/Reperfusion. model. The
cells were suspended by 0.4% trypsin without EDTA. Yellow line: The vehicle. were treated with 5 μM of Probe 1 in
PBS for 15 min. Orange line: OGD model. Green line: Reperfusion model.

study using the MCAO model (Figure 3.12). Precedent studies indicate high elevated levels
of Fe(II) in the ischemic tissue of the brain. Indeed, the Fe(II) is much higher than that at the
nonischemic site (Non-I). Moreover, the DFO retreatment successfully inverted the ischemiainduced fluorescence intensity increase (right side, Non-I + DFO and I + DFO). These studies
indicate that the Probe 1 has the capacity to probe the Fe(II) in the brain tissue of a rat
undergoing ischemic stroke.
We also performed Fe(II) imaging study under ICH animal model (Figure 3.13).165 However,
unexpectedly, we observed different results in the hemorrhagic model. No change of labile
iron in the ICH side (left side), especially around the bleeding site, is observed. Instead, Fe(III)
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level is increased (Figure 3.14). Recently it was reported that the neuronal death after
hemorrhagic stroke shares features of ferroptosis and necroptosis. Unlike apoptosis, in the
ferroptosis and necroptosis, the mitochondria outer membrane ruptures and the content releases.
The labile iron and iron bounding protein in the mitochondria also releases into the cytosol to
balance Fe(II)/Fe(III) redox.
Non-I

I

Non-I + DFO

I + DFO

Figure 3.12. Fluorescent images of labile Fe(II) in rat’s ischemic brain tissue. Brain sections were incubated with
5.0 μM Probe 1 for 15 min at the nonischemic side (Non-I) and at the ischemic side (I). Sections were pretreated
with DFO (50.0 μM) for 1 h then 5.0 μM Probe 1 for another 15 min at the nonischemic site with DFO pretreatment
(Non-I + DFO) and at the ischemic site with DFO pretreatment (I + DFO).
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H

Non-H

H + DFO

Non-H + DFO

Figure 3.13. Fluorescent images of labile Fe(II) in rat’s intracerebral hemorrhagic brain tissue. Brain sections were
incubated with 5.0 μM Probe 1 for 15 min at the nonhemorrhagic side (Non-H) and at the hemorrhagic side (H).
Sections were pretreated with DFO (50.0 μM) for 1 h then 5.0 μM Probe 1 for another 15 min at the nonischemic
site with DFO pretreatment (Non-H + DFO) and at the ischemic site with DFO pretreatment (H + DFO).
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Non-H

H

Figure 3.14 Fluorescent images of labile Fe(III) in rat’s intracerebral hemorrhagic brain tissue. Brain sections were
incubated with 5.0 μM Fe(III) probe for 15 min at the nonhemorrhagic side (Non-H) and at the hemorrhagic side
(H).

3.6. Conclusion
A novel mitochondrial specific Fe(II) probe was designed and synthesized based on our
developed N-O bond chemistry. The probe exhibited a sensitive and selective turn-on response
against Fe(II). Application to live-cell imaging showed mitochondria accumulation and labile
iron pools at endogenous basal levels were detectable by both live-cell imaging and flow
cytometry. The fluctuation of iron Fe(II) concentration was directly observed in mitochondria
respiratory failure induced by zinc, nystatin, or OGD/reperfusion model in the cellular level.
The probe holds great potential for the study of Fe(II) associated pathology.
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3.7. Experiment section

General Information: Commercial reagents were used as received unless otherwise stated.
Merck 60 silica gel was used for chromatography, and Whatman silica gel plates with
fluorescence F254 were used for thin-layer chromatography (TLC) analysis.
Spectroscopic Materials and Methods: Fluorescence emission spectra were obtained on a
SHIMADZU spectrofluorophotometer RF-5301pc. The UV absorption spectra were obtained
on a SHIMADZU UV-1800.
1

H and 13C NMR spectra were recorded on Bruker Avance 500 and Bruker tardis (sb300). The

signals in 1H and 13C NMR spectra were referenced to the residual peak of a deuterated solvent.
Data for 1H are reported as follows: chemical shift (ppm), and multiplicity (s = singlet, d =
doublet, t = triplet, q = quartet, m = multiplet, br = broad). Data for 13C NMR are reported as
ppm.
Cell Culture: All cells were cultured in DMEM medium (Gibco) supplemented with 10% FBS,
2 mM Gluta MAX (Life Technologies), 100 U/mL penicillin (Life Technologies) and 100
μg/mL streptomycin (Life Technologies) at 37 °C in a humidified atmosphere containing 5%
CO2. Due to the strong binding affinity between Fe(II) and EDTA, trypsin used for lysis in the
whole project is excluded with EDTA.
Cell Viability Assay: Cell viability was determined by the MTT assay. Cells (5 × 104/well)
were seeded in a 96-well plate overnight before treatment with the corresponding compound
for designed time. After the exchange of the medium to pure DMEM, 20 μl of the MTT solution
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(5 mg/ml) was added to each well and incubated at 37 °C for 2 h. The supernatant was removed,
and the insoluble formazan product was dissolved in 100 μl of DMSO. The absorbance of each
culture well was measured with a microplate reader (Molecular Devices, USA) at a wavelength
of 570 nm.
Flow Cytometry Analysis: The cell was cultured with Cell samples were trypsinized and
washed with PBS twice. The endogenous Fe(II) group was treated with 5 μM of Probe 1 in
PBS for 15 min. negative group was treated with 20 μM DFO 15 min and then with 5 μM of
Probe 1 for 15 min in PBS. The positive group was treated with 100 μM exogenous Fe(II) for
15 min in PBS, after washout, further treated with 5 μM of Probe 1 for 15 min. Fe(II) level
was analyzed by flow cytometry and 10 K cells were counted for each condition. Mean
fluorescence intensity for all counted cells in each condition was obtained by BD Accuri C6
Plus flow cytometer. Experiments were conducted in triplicate or quadruplicate.
Fluorescence Microscopy and Statistical Analysis: Zeiss Axio Observer. D1 outfitted with
HBO 100 microscopy illumination system (RhB channel: excitation, 555 nm; and emission,
580 nm) was used to take fluorescence images for Fe(II) probe in the described experiments
for the following statistical analysis. DAPI and LysoTracker blue were detected through the
DAPI channel and MitoTracker green was detected through the GFP channel. Cell images were
collected from five different areas (four quarters and center) in each of the three independent
experiments. Fluorescence analysis as described above using ImageJ.
OGD Model: The cell was cultured in the normal condition in the six-well plate overnight.
The model was established by treating the cell with low oxygen and no glucose condition for
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1.5 h in the hypoxia chamber at 37 °C. Reperfusion model was obtained by OGD model recover
glucose and oxygen for 30 min. The cell was treated with Probe 1 or Fe(III) probe for 15 min.
The suspended sample was detected by Flow cytometry directly. (PE channel).
Animal Model of Focal Cerebral Ischemia: The Laboratory Animal Care and Use
Committee at the University of New Mexico approved all experimental protocols. Male
Sprague−Dawley rats (Charles River) weighing 290 to 320 g were subjected to 1.5 h of MCAO
followed by 5 min of reperfusion using the intraluminal suture occlusion model, as we
described previously. Rats were anesthetized with 2% isoflurane during surgical procedures.
Prior to reperfusion, all rats included in this study displayed neurologic deficit typical of
MCAO, circling to the left (nonischemic side).
At the end of reperfusion, the rats were transcardially perfused with ice-cold PBS and 4%
paraformaldehyde, and then the brain was quickly taken out. The brain tissue was frozen in
optimal cutting temperature (OCT) solution for cryosectioning. A set of 20-μm-thick brain
sections was generated from the selected brain region (+1.5 to −3.5 mm relative to the bregma).
After washing with PBS three times, the sections were incubated with 0.3% Triton X-100.
Then, the probe was added onto the sections. Following by 15 min incubation and thorough
washing, each section was photographed under the Olympus IX-81 microscope with Stereo
Investigator software (Olympus, Optical Co. Ltd., Japan).
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Synthesis of Probe 1
O
O
N

OH

OH

2-(2-Hydroxybenzoyl)benzoic acid166
To 3-(diethylamino)phenol (3g, 18.16 mM) in 30 mL toluene, phthalic anhydride (2.82g,
19.04 mM) was added, then the mixture was heated to reflux and stirred for 12 h. After cooled
to room temperature, the solvent was removed by rotavapor. The left solid was washed with a
large amount of ethyl acetate and dried with oil pump. Without further purification, the product
was obtained as a purple solid (8.4 g, 84%). 1H NMR (300 MHz, DMSO): 1H NMR (300 MHz,
CDCl3): δ 8.11 (d, J = 7.5Hz, 1H), 7.64 (t, J = 6.9Hz, 1H), 7.54 (t, J = 7.8Hz, 1H), 7.38 (d, J =
7.5Hz, 1H), 6.89 (d, J = 9Hz, 1H), 6.15 (d, J = 2.4Hz, 1H), 6.05 (dd, J = 2.3Hz, 9.2Hz, 1H),
3.38 (q, J = 7.1Hz, 4H), 1.19 (t, J = 7.1Hz, 6H).

3'-(Diethylamino)-6'-nitro-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one
To compound 2-(2-hydroxybenzoyl)benzoic acid (420 mg, 1.34 mM) in 20 mL MeSO3H,
3-nitrophenol (280 mg, 2.01 mM) was added, then heated to 130 ℃ and stirred for 48 h. The
mixture was cooled to room temperature, then 40 mL H2O was added. The crude product was
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extracted with DCM (100 mL × 3). Combined organic phase was washed with water (50 ml ×
3) and dried over Na2SO4. The product was purified through column chromatography and
obtained as a yellow solid (240 mg, 43%). 1H NMR (300 MHz, CDCl3): δ 8.13 (d, J = 2.1Hz,
1H), 8.06-8.03 (m, 1H), 7.81 (dd, J = 2.4 Hz, 8.7 Hz, 1H), 7.72-7.62 (m, 2H), 7.18 (dd, J = 1.2
Hz, 6.3 Hz, 1H), 6.96 (d, J = 8.7 Hz, 1H), 6.60 (d, J = 9 Hz, 1H), 6.49 (d, J = 2.4 Hz, 1H), 6.41
(dd, J = 2.7 Hz, 9 Hz, 1H), 3.38 (q, J = 7.10 Hz, 4H), 1.18 (t, J = 7.05 Hz, 6H). 13C NMR (75
MHz, CDCl3): 169.11, 152.56, 152.45, 151.88, 149.95, 148.72, 135.25, 130.08, 129.32, 128.80,
126.63, 126.04, 125.29, 123.89, 117.54, 112.88, 109.18, 103.86, 97.49, 82.44, 44.55, 12.46.

O
O
HO

N
H

O

N

Probe 1
To

compound

3'-(diethylamino)-6'-nitro-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one

(230 mg, 0.55 mM) in 20 mL MeOH. zinc powder (722 mg, 11.04 mM) and NH4Cl (590 mg,
11.03 mM) was added, then the mixture was heated to reflux and stirred for 1.5 h. After cooling
to room temperature, the solid in solution was removed by filtration, and the solvent was
removed by rotavapor. The product was purified through column chromatography and obtained
as pink solid (180 mg, 81%). 1H NMR (300 MHz, CD3OD): δ 7.72 (dd, J = 1.5Hz, 7.8Hz, 1H),
7.25-7.19 (m, 1H), 7.14-7.08 (m, 1H), 6.96 (dd, J = 1.05Hz, 8.1Hz, 1H), 6.85-6.77 (m, 2H),
6.45 (d, J = 2.4Hz, 1H), 6.38 (d, J = 2.4Hz, 1H), 6.35-6.30 (m, 2H), 6.11 (s, 1H), 3.30 (q, J =
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7.00Hz, 4H), 1.09 (t, J = 6.9Hz, 6H). 13C NMR (75 MHz, CD3OD): 172.57, 153.15, 153.03,
150.36, 148.38, 148.07, 132.66, 132.32, 131.96, 131.55, 129.97, 126.56, 116.54, 114.53,
112.41, 109.68, 103.70, 100.76, 45.94, 38.42, 12.75. HRMS (ESI): calcd. for C24H22N2O4
[M+H]+: 403.1658, found, 403.1715.

3'-Amino-6'-(diethylamino)-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one
To compound 5a (217 mg, 0.69 mM) in 8 mL of MeSO3H, 3- aminophenol (80 mg, 0.73
mM) was added, then heated to 130 °C and stirred for 20 h. The mixture was cooled room
temperature, and 40 mL of H2O was poured followed by excessive TEA. The solution was
extracted by CH2Cl2 (40 mL × 2) and dried over Na2SO4. The product was purified through
column chromatograph, and the obtained product was dissolved in 30 mL of CH2Cl2, and
washed with dilute aqueous NaOH, dried over Na2SO4. Finally, the product was obtained as a
red solid (150 mg, 56%). 1H NMR (300 MHz, CDCl3): δ 7.99 (dd, J = 1.2Hz, 6.6Hz, 1H), 7.627.54 (m, 2H), 7.17 (dd, J = 1.2Hz, 6.9Hz, 1H), 6.58-6.42 (m, 4H), 6.35-6.25 (m, 2H), 3.33 (q,
J = 7.10Hz, 4H), 1.15 (t, J = 7.05Hz, 6H).

13

C NMR (75 MHz, CDCl3): δ 169.94, 153.23,

153.14, 152.53, 149.66, 149.10, 134.45, 129.31, 129.23, 129.00, 128.02, 124.89, 124.29,
111.43, 109.21, 108.28, 105.82, 101.21, 97.55, 77.35, 44.50, 12.55. HRMS (ESI): calcd. for
C24H22N2O3 [M+H]+: 387.1709, found: 387.1711.
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Chapter 4. Oxime Caged Ketone Theragnostic Prodrugs
Enabled by Photo-triggered Release with Blue LED
Abstract
The development of photo-triggers for controlled release of caged bioactive molecules
have received considerable interest in drug delivery and biomedical research by virtue of the
non-contact action mode and spatiotemporal control capacity of light. Photo-triggers generally
employ UV light, which induces significant toxicity and cell damage. To overcome this
limitation, new photo-triggers with long wavelength cleavage are in high demand. Moreover,
the current researches mainly focus on caging limited types of functional groups, such as
hydroxyl, amino, and carboxylic group. It is necessary to develop photo-triggers for ketone
since they are widely present in bioactive molecules and therapeutics. In this project, we prove
the concept of a photo-triggered release of ketone drugs - flubendazole and mebendazole as
examples. Their oxime caged theragnostic prodrugs are inactive. Irradiation the prodrugs with
blue LED can break the N-O bond and subsequently generate the bioactive parent drugs and
imaging probe. We believe this novel photo-triggered cage system holds potential for the
controlled release of functional molecules for the study of mechanism of action in signaling
pathways and for drug delivery with reduced side effects.
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4.1. Introduction

Photo-triggers, also known as photoremovable protecting groups, were originally developed
for functional group protection in organic synthesis.167 Taking the advantage of the non-contact
action mode, the development and potential bio-application of photo-triggers have aroused
great interest among both chemists and biologists as essential molecular tools for the photoregulation of proteins,168 genes,169 cells,170, and even therapy.171 A bioactive compound is
caged by a photosensitive group through a covalent bond to form an inactive prodrug. When
the prodrug is distributed into the body, the light irradiates the lesion site and induces the
cleavage of prodrug and released the bioactive compound at desired site. UV photo-triggered
release has been subject to extensive research due to the high energy of UV light and
convenient design of light absorbent photo-trigger moiety. However, when those compounds
are simply grafted to biological research, the significant limitation appears. The UV light is
absorbed by the biomolecule, such as DNA, RNA and tryptophan in proteins, which not only
induced significant toxicity, but also limited penetration of the UV light as well.172,173 To
overcome this intrinsic limitation, new photo-trigger with longer wavelength cleavage is highly
desired in biomedical science. Furthermore, the available caged groups are very limited, and
they are mainly used for the cage of amino, hydroxyl, and carboxylic groups. New cage groups
are highly sought to meet the demand for structurally diverse biologically active compounds.
Based on our group’s previous study on N-O chemistry, the N-O bond is prone to be cleaved
through a unique homolytic radical process.29 We hypothesize that it is possible to break an
62

oxime N-O bond by the light in the presence of a photosensitizer. Caging of a ketone by oxime
can be readily achieved by click reaction of ketones and hydroylamines. It is noted that the
ketone is widely present in the drug and other bifunctional molecules.174-182 Realization of the
new cage approach will expand the scope of the photo-caging tool.
Toward this end, we have developed a photochemical approach to cleave the N-O bond in
oximes to release caged ketones. As demonstrated, the caged prodrugs for flubendazole and
mebendazole are inactive. However, the light triggered release of the drugs and showed full
recovery of bio-activity. Moreover, the drug-release event was tracked by the fluorescence
imaging with concurrent generation of fluorescence species.
4.2. Prodrug design
In a model system, irradiation of the oxime caged diphenylketone in the presence of
photosensitizer (PS) eosin Y was able to release the ketone but with very low reaction
efficiency (Scheme 4.1). The low cleavage efficiency may be due to the use of external PS.
Therefore, we designed a new photo-trigger prodrug system by incorporation of a PS into it
through the oxime bond. Such a design showed several advantages. 1) cleavage efficiency is
higher since absorbed energy was transferred through bond intramolecularly. 2) Both cleaved
moieties are functional as theragnostic agent. One of them is the desired drug, which creates
the therapeutic effect, and another moiety is a fluorophore, which can monitor and/or quantify
the cleavage and was possible to apply for diagnosis. In our studies, we used ketone drugs
mebendazole and flubendazole as showcase. They are used as anthelmintic capable of
disrupting microtubule. They are also repurposed as anti-cancer agents.183-187 The other moiety
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is a PS. Our earlier studies showed an electron deficient moiety is required to weaken N-O
bond in the oxime. We chose 7-nitrobenzofurazan (NBD) as the PS.188-191 The incorporated
NBD is non-fluorescent. Upon decaged, the fluorescent molecule is generated.
Scheme 4.1. The model reaction of N-O bond in the oxime cleaved by photosensitizer.

The designed theragnostic prodrugs Mebendazole-NBD and Flubendazole-NBD can be
synthesized from commercially available flubendazole, mebendazole and 4-chloro-7nitrobenzofurazan in 2 steps (Scheme 4.2). Oxime formation is followed by the incorporation
of NBD moiety. We found that the prodrugs are stable for more than one month under the dark
condition at -20 °C without significant decay based on 1H NMR analysis.
Scheme 4.2. Synthesis of Mebendazole-NBD and Flubendazole-NBD
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4.3. Release study of Mebendazole-NBD and Flubendazole-NBD prodrugs in chemical
system

Having the desired photo-trigger prodrugs in hand, we tested their cleavage efficiency in
chemical medium (Figure 4.1 and 4.2). The HPLC analysis showed that the cleavage was
thorough, and the product was mainly mebendazole or flubendazole. GSH was used to quench
the radical intermediates to generate drug release. In cellular studies, particularly in cancer
cells, GSH is present. Therefore, no external GSH is needed.

Figure 4.1. The photocleavage reaction for Flubendazole-NBD in buffer. The reaction was detected by HPLC. Reaction
condition 100 μM substrate and 2-fold of GSH in HEPES buffer Blue LED stir for 1h.
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Figure 4.2. The photocleavage reaction for Mebendazole-NBD in buffer. The reaction was detected by HPLC. Reaction
condition 100 μM substrate and 2-fold of GSH in HEPES buffer Blue LED stir for 1h.

Interestingly, the photo-trigger prodrugs only responded for the light with less than 420 nm
wavelength, and were inert under 490 nm irradiation, which was the maximum fluorescence
excitation wavelength for the uncaged photosensitizer moiety, NBDOH (Figure 4.3 and 4.4).
Taking advantage of the fluorescence character of the cleaved photosensitizer moiety, NBDOH,
we monitored the cleavage reaction synergistically by fluorescence spectroscopy (Figure 4.5
and 4.6). The reaction showed linear kinetics indicating the first order reaction, which matched
single molecule participating reaction with light as driving force. No matter present GSH or
not, the reaction of mebendazole has similar reaction rates since the driving force of the
cleavage was the absorption of light by the intracellular photosensitizer moiety, and GSH only
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participated the subsequent radical quench. After obtaining the standard curve of fluorescence
of NBDOH (Figure 4.6 and 4.7), the reaction rate of Mebendazole-NBD was calculated at 2.8
× 10-3 s-1 and t1/2 is 2500 s. For Flubendazole-NBD, the reaction rate is 4.0 × 10-3 s-1 and t1/2 is
1850 s. The UV-Vis spectra of Mebendazole-NBD, Mebendazole and NBDOH (Figure 4.8)
reveal that the maximum absorption of Mebendazole-NBD is around 410 nm and only have
very weak absorption at 490 nm. In contrast, NBDOH have a strong absorption peak at 490
nm. This may explain why the prodrugs are more sensitive to the irradiation at 420 nm.
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Figure 4.3. Fluorescence spectra for Mebendazole-NBD. The spectrum was detected under two wavelengths. 390 nm is
a suitable cleavage wavelength. And the compound is stable for 490 nm light. The emission is detected at 556 nm.
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Figure 4.4. Fluorescence spectrum for Flubendazole-NBD. The spectrum was detected under two wavelengths. 390 nm
is a suitable cleavage wavelength. And the compound is stable for 490 nm light. The emission is detected at 556 nm.
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Figure 4.5. UV-Vis absorption of photo-trigger Flubendazole-NBD and its cleavage product NBDOH and flubendazole.
1 mM of corresponding compound was dissolved in HEPES buffer in the presence of 10% ethanol to assist solubility.
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Figure 4.6. Fluorescence spectrum for NBDOH with gradient concentrations. The excitation wavelength is 390 nm.
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Figure 4.7. Standard curve of fluorescence intensity for NBDOH with gradient concentrations. The excitation wavelength
is 390 nm and the emission wavelength is 594 nm.
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Figure 4.8. UV-Vis absorption of photo-trigger Flubendazole-NBD and its cleavage product NBDOH and flubendazole.
1 mM the corresponding compound was dissolved in HEPES buffer in the presence of 10% ethanol to assist solubility

4.4. Release study of Mebendazole-NBD and Flubendazole-NBD prodrugs in cells
After demonstrating the feasibility of the release of the photo-trigger prodrugs in chemical
system, we extended the study in cells using HeLa and MCF-3 cells. Both cells were treated
with Mebendazole-NBD and Flubendazole-NBD prodrugs. It was found that they are
relatively non-toxic in the dark (LC50 > 10 μM(Mebendazole-NBD)). In contrast, after exposure by
blue LED for 1 h, the caged compounds were discomposed and biologically active drug
mebendazole or flubendazole was released. The cell viability for both HeLa and MCF-7 in the
light exposure group are almost the same as the positive control group (LC50: 1.05
μM(Mebendazole-NBD) v.s. 1.13 μM

(Mebendazole)

in the 24 h test for HeLa cell). The data indicated

the release of the photo-trigger prodrugs was efficient. It is noteworthy that the selectivity for
the cancer cell-line is significant for the new prodrugs and can reduce side effect of cancer
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therapy.
120

Mebendazole
Mebendazole-NBD light 1h
Mebendazole-NBD
NBDOH

Cell Viability (%)

100

*

*

*

*

**

***
***

80

60

40

***

***

***

20

0

None

0.1 μM

0.5 μM

1.0 μM

***

5.0 μM

***
***

10 μM

24 h HeLa
Figure 4.9. Cell viability of HeLa cell treated with Mebendazole and its prodrug. Hela cell was cultured in the 96 wells
plate. After treated with the drug, the group with light was radiated under blue LED for 1h. the temperature is under 37 ℃,
and then it was cultured with other groups in the same condition. After 24 h of culture, the cell viability was measured by
MTT assay. Data are mean relative cell viability ± s.e.m. across triplicates.
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Figure 4.10. Cell viability of HeLa cell treated with Flubendazole and its prodrug. The cell was cultured in the 96 wells
plate. After treated with the drug, the group with light was radiated under blue LED for 1h. the temperature is under 37 ℃,
and then it was cultured with other groups in the same condition. After 24 h of culture, the cell viability was measured by
MTT assay. Data are mean relative cell viability ± s.e.m. across triplicates.
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Figure 4.11. Cell viability of MCF-7 cell treated with mebendazole and its prodrug. The cell was cultured in the 96 wells
plate. After treated with the drug, the group with light was radiated under Blue LED for 1h. the temperature is under
37 ℃, and then it was cultured with other groups in the same condition. After 72 h of culture, the cell viability was
measured by MTT assay. Data are mean relative cell viability ± s.e.m. across triplicates.
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Figure 4.12. Cell viability of MCF-7 cell treated with Flubendazole and its prodrug. The cell was cultured in the 96 wells
plate. After treated with the drug, the group with light was radiated under Blue LED for 1h. the temperature is under
37 ℃, and then it was cultured with other groups in the same condition. After 72 h of culture, the cell viability was
measured by MTT assay. Data are mean relative cell viability ± s.e.m. across triplicates.

Besides uncaged of the drug moiety, the photosensitizer moiety NBDOH was also released
concurrently with strong fluorescence. The capacity enables the spatiotemporal monitoring
drug distribution. The fluorescence image showed significant intensity increase after
Mebendazole-NBD was treated with blue LED for 1h, which fluorescence matched with the
same concentration NBDOH indicated the high efficiency of fluorophore moiety recovery. The
light treated group has significantly less living cell than the positive control group or the dark
group in the bright field channel indicated the cytotoxicity is from the drug moiety instead of
NBDOH. (Figure 3.13)
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Dark

Blue LED 1h

NBDOH

Figure 4.13. Fluorescence image to tracking the photo-trigger cleavage. After treated HeLa cell with Mebendazole-NBD
(10 μM), the group with light was radiated under Blue LED for 1h. the temperature is under 37 ℃, and then it was cultured
with other groups in the same condition. After 12 h of culture, the cells were washed with PBS once, and then take the
fluorescence image. The positive group (right) was obtained by NBDOH 10 μM treatment for 12 h.

4.5. Conclusion

We have demonstrated the concept of photo-trigger for ketones, which is widely present in
current medicine and challenged by the previous methodology. The caged compound for
flubendazole and mebendazole is inactive under the dark condition, and the light triggered
releasing of the drugs showed fully bio-active recovery of both drug and fluorophore. This
fundamentally novel photo-trigger is possible to be further applied for biology and drug
development.
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4.6. Experiment section

General Information: Commercial reagents were used as received unless otherwise stated.
Merck 60 silica gel was used for chromatography, and Whatman silica gel plates with
fluorescence F254 were used for thin-layer chromatography (TLC) analysis.
Spectroscopic Materials and Methods: Fluorescence emission spectra were obtained on a
SHIMADZU spectrofluorophotometer RF-5301pc. The UV absorption spectra were obtained
on a SHIMADZU UV-1800.
1

H and 13C NMR spectra were recorded on Bruker Avance 500 and Bruker tardis (sb300). The

signals in 1H and 13C NMR spectra were referenced to the residual peak of a deuterated
solvent.
Data for 1H are reported as follows: chemical shift (ppm), and multiplicity (s = singlet, d =
doublet, t = triplet, q = quartet, m = multiplet, br = broad). Data for 13C NMR are reported as
ppm.
Cell Culture: All cells were cultured in DMEM medium (Gibco) supplemented with 10% FBS,
2 mM Gluta MAX (Life Technologies), 100 U/mL penicillin (Life Technologies) and 100
μg/mL streptomycin (Life Technologies) at 37 °C in a humidified atmosphere containing 5%
CO2.
Cell viability assay: Cell viability was determined by the MTT assay. Cells (5 × 104/well)
were seeded in a 96-well plate overnight before treatment with the corresponding compound.
After treated with drug, the group with light was radiated under Blue LED for 1h. the
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temperature is under 37 °C, and then it was culture with other group in the same condition.
After the exchange of the medium to pure DMEM, 20 μL of the MTT solution (5 mg/mL) was
added to each well and incubated at 37 °C for 2 h. The supernatant was removed, and the
insoluble formazan product was dissolved in 100 μl of DMSO. The absorbance of each culture
well was measured with a microplate reader (Molecular Devices, USA) at a wavelength of 570
nm.
Fluorescence Microscopy and Statistical Analysis: Zeiss Axio Observer. D1 outfitted with
HBO 100 microscopy illumination system (RhB channel: excitation, 555 nm; and emission,
580 nm) was used to take fluorescence images for Fe(II) probe in the described experiments
for the following statistical analysis. DAPI and LysoTracker blue were detected through the
DAPI channel and MitoTracker green was detected through the GFP channel. Cell images were
collected from five different areas (four quarters and center) in each of the three independent
experiments. Fluorescence analysis as described above using ImageJ.
Reverse-Phase HPLC Analysis: HPLC chromatograms were acquired using DionexUltiMate 3000 LC System with Acclaim 120 Å, C18, 3 μm analytical (4.6 × 100 mm) column.
Chromatographic conditions: eluent A, 0.1% v/v TFA in water; eluent B, 0.1% v/v TFA in
acetonitrile. Samples in DMSO was eluted at a flow rate of 0.750 mL/min monitored at a
wavelength of 254 nm. From 0 to 10 min: 90% A, 10% B. From 10 to 18 min (linear): 90% A,
10% B to 5% A, 95% B. From 18 min to 20 min 5% A, 95% B. Generation of uncaged drug
was quantified by the peak area of product out of the total peak area.
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Compound Synthesis

Diphenylmethanone O-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl) oxime
To diphenylmethanone oxime (19.6 mg, 0.1 mmol) and NBDCl (20.0 mg, 0.1 mmol) in 1
ml THF was added K2HPO4 (38.4 mg, 0.2 mmol) and 18crown6 (26.4 mg, 0.1 mmol), then the
mixture was stirred at room temperature overnight without light. 5 ml EA and 5 ml water were
added into the mixture, the organic layer was separated out and washed with saturated aq.
NaHCO3 5 ml and dried over Na2SO4. The product was purified through column
chromatography and obtained as a yellow solid. (27.3 mg, 76%) 1H NMR (500 MHz, CDCl3):
δ 7.44-7.50 (m, 4H), 7.50-7.59 (m, 4H), 7.65 (d, J = 7 Hz, 2H), 8.60 (d, J = 7.5 Hz, 1H). 13C
NMR (125 MHz, CDCl3): δ 107.1, 128.6, 128.8, 129.3,129.6,130.2, 130.8, 131.2, 131.7, 134.2,
134.3, 143.6, 144.1, 154.0, 165.9.

Mebendazole oxime
To mebendazole (295 mg, 1.0 mmol) and NH2OH (278 mg, 4.0 mmol) in 50 ml MeOH was
added anhydrous NaOAc (164 mg, 2.0 mmol). The mixture was refluxed overnight. After
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cooling down, 50 mL of water was added. The solid was filtered out and washed with water
(50 mL × 3) and ethanol (50 ml × 3). After drying by oil pump, the product was obtained as
white solid (270 mg, 87%, E/Z isomer mixture). 1H NMR (500 MHz, DMSO): δ 3.725 (s, 3H),
7.21 (m, 1H), 7.28 (d, J = 7.5 Hz, 2H), 7.35-7.48 (m, 5H), 11.1 (s, 1H), 11.7 (b, 2H). 13C NMR
(125 MHz, DMSO): δ 18.9, 52.8, 56.4, 120.7, 128.4, 128.5, 129.3, 134.7, 156.3

Flubendazole oxime
To flubendazole (313 mg, 1.0 mmol) and NH2OH (278 mg, 4.0 mmol) in 50 ml MeOH was
added anhydrous NaOAc (164 mg, 2.0 mmol). The mixture was refluxed overnight. After
cooling down, 50 ml water was added in. The solid was filtered out and washed with water (50
mL × 3) and ethanol (50 mL × 3). After drying by oil pump, the product was obtained as white
solid. (298 mg, 91%) E/Z isomer mixture. 1H NMR (500 MHz, DMSO): δ 3.81 (s, 1.59H),
3.83(s, 1.41H), 7.11-7.57(m, 8H), 11.3 (s, 0.53H), 11.4 (s, 0.49H), 12.3 (b, 2H). 13C NMR (125
MHz, DMSO): δ 18.9, 53.4, 56.4, 115.4,115.5,115.7, 129.6, 129.7, 131.6,131.7,134.1, 154.9,
161.2.
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Mebendazole-NBD
To mebendazole oxime (31.0 mg, 0.1 mmol) and NBDCl (40.0 mg, 0.2 mmol) in 1 ml
DMSO was added K2HPO4 (38.4 mg, 0.2 mmol) and 18-crown-6 (26.4 mg, 0.1 mmol), then
the mixture was stirred at room temperature for 72 h without light. 50 mL of DCM and 5 mL
of water were added into the mixture, the organic layer was separated out and washed with
saturated aq. NaHCO3 (5 mL) and dried over Na2SO4. The product was purified through
column chromatography and obtained as a yellow solid. (14.6 mg, 31%) 1H NMR (500 MHz,
DMSO): δ 3.76 (s，1H), 7.50-7.53 (m, 4H), 7.60-7.67 (m, 4H), 7.66 (d, J = 8.5 Hz, 1H), 8.79
(d, J = 8.5 Hz, 1H). 13C NMR (125 MHz, CDCl3): δ 48.6, 52.6, 121.8, 128.5, 129.0, 130.2,
131.8, 136.0, 143.7, 144.2, 135.1, 166.3.

Flubendazole-NBD
To flubendazole oxime (32.8 mg, 0.1 mmol) and NBDCl (40.0 mg, 0.2 mmol) in 1 mL of
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DMSO was added K2HPO4 (38.4 mg, 0.2 mmol) and 18-crown-6 (26.4 mg, 0.1 mmol), then
the mixture was stirred at room temperature for 72 h without light. 50 mL of DCM and 5 mL
of water were added into the mixture, the organic layer was separated out and washed with
saturated aq. NaHCO3 (5 mL) and dried over Na2SO4. The product was purified through
column chromatography and obtained as a yellow solid. (16.3 mg, 43%) 1H NMR (500 MHz,
DMSO): δ 3.79 (s，3H), 7.24 (d, J = 8.0 Hz, 1H), 7.36-7.73 (m, 7H), 7.66 (d, J = 8.5 Hz, 1H),
8.79 (d, J = 8.5 Hz, 1H).

diphenylmethanone O-(2,4-dinitrophenyl) oxime
To diphenylmethanone oxime (19.6 mg, 0.1 mmol) and 1-chloro-2,4-dinitrobenzene (20.2
mg, 0.1 mmol) in 1 mL of THF was added K2HPO4 (38.4 mg, 0.2 mmol), then the mixture was
stirred at room temperature overnight. 5 mL of EA and 5 mL of water were added into the
mixture, the organic layer was separated out and washed with saturated aq. NaHCO3 (5 mL)
and dried over Na2SO4. The product was purified through column chromatography and
obtained as a yellow solid. (26.1 mg, 72%) 1H NMR (500 MHz, CDCl3): δ 7.43-7.53 (m, 7H),
7.62 (d, J = 8 Hz, 1H), 8.15 (d, J = 9.5 Hz, 1H), 8.47 (dd, J = 9.5 Hz, 2.5 Hz, 1H), 8.83 (d, J =
2.5 Hz, 1H).
81

Additional cell viscosity data
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Figure S4.1. cell viability of HeLa cell treated with mebendazole and its prodrug. HeLa cell was cultured in the 96 wells plate.
After treated with the drug, the group with light was radiated under blue LED for 1h. the temperature is under 37 ℃, and then
it was culture with other groups in the same condition. After 48 h of culture, the cell viability was measured by MTT assay.
Data are mean relative cell viability ± s.e.m. across triplicates.
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Figure S4.2. cell viability of HeLa cell treated with mebendazole and its prodrug. HeLa cell was cultured in the 96 wells plate.
After treated with the drug, the group with light was radiated under blue LED for 1h. the temperature is under 37 ℃, and then
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it was culture with other groups in the same condition. After 72 h of culture, the cell viability was measured by MTT assay.
Data are mean relative cell viability ± s.e.m. across triplicates.
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Figure S4.3 cell viability of HeLa cell treated with Flubendazole and its prodrug. HeLa cell was cultured in the 96 wells plate.
After treated with the drug, the group with light was radiated under blue LED for 1h. the temperature is under 37 ℃, and then
it was culture with other groups in the same condition. After 48 h of culture, the cell viability was measured by MTT assay.
Data are mean relative cell viability ± s.e.m. across triplicates.
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Figure S4.4. cell viability of HeLa cell treated with Flubendazole and its prodrug. HeLa cell was cultured in the 96 wells plate.
After treated with the drug, the group with light was radiated under blue LED for 1h. the temperature is under 37 ℃, and then
it was culture with other groups in the same condition. After 72 h of culture, the cell viability was measured by MTT assay.
Data are mean relative cell viability ± s.e.m. across triplicates.
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Figure S4.5. cell viability of MCF-7 cell treated with Mebendazole and its prodrug. HeLa cell was cultured in the 96 wells
plate. After treated with the drug, the group with light was radiated under blue LED for 1h. the temperature is under 37 ℃,
and then it was culture with other groups in the same condition. After 24 h of culture, the cell viability was measured by MTT
assay. Data are mean relative cell viability ± s.e.m. across triplicates.
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Figure S4.6. cell viability of MCF-7 cell treated with Mebendazole and its prodrug. HeLa cell was cultured in the 96 wells
plate. After treated with the drug, the group with light was radiated under Blue LED for 1h. the temperature is under 37 ℃,
and then it was culture with other groups in the same condition. After 48 h of culture, the cell viability was measured by MTT
assay. Data are mean relative cell viability ± s.e.m. across triplicates.
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Figure S4.7. cell viability of MCF-7 cell treated with Flubendazole and its prodrug. HeLa cell was cultured in the 96 wells
plate. After treated with the drug, the group with light was radiated under Blue LED for 1h. the temperature is under 37 ℃,
and then it was culture with other groups in the same condition. After 24 h of culture, the cell viability was measured by MTT
assay. Data are mean relative cell viability ± s.e.m. across triplicates.
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Figure S4.8. Cell viability of MCF-7 cell treated with Flubendazole and its prodrug. HeLa cell was cultured in the 96 wells
plate. After treated with the drug, the group with light was radiated under Blue LED for 1h. the temperature is under 37 ℃,
and then it was culture with other groups in the same condition. After 24 h of culture, the cell viability was measured by MTT
assay. Data are mean relative cell viability ± s.e.m. across triplicates.
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Chapter 5. Fe(III), the Direct Intracellular Ferroptosis Inducer instead
of Fe(II)
Abstract
Ferroptosis is a new type of iron-relative programmed cell death, characterized as the
glutathione depletion and the peroxidation damage of lipid. It was associated with the
degenerative illness, neoplastic diseases, and ischemic injury. The role of iron (Fe(II) and
Fe(III)) played in the ferroptosis process is still unclear. The data described in this study
showed that labile Fe(III) is the real ferroptosis inducer instead of labile Fe(II). We reported
hydroxylamines as new ferroptosis inhibitors through the reduction of Fe(III) to Fe(II). In
contrast, tBuOOH, the oxidant of Fe(II), is ferroptosis inducer through oxidation of Fe(II) to
Fe(III). Removal of Fe(III) by the chelator of Fe(III) inhibited the ferroptosis, but the chelator
of Fe(II) has no significant relationship with ferroptosis.

5.1 Introduction

In recent years, it has been recognized that in addition to apoptosis, there are other
mechanisms manipulate the demise of the cell.192-195 The studies have a series of different type
of regulated cell death, including necroptosis,196 autophagy,197 and ferroptosis.147
As an iron-dependent form of regulated cell death, ferroptosis is characterized as the
glutathione depletion and peroxidation damage of lipid (Scheme 5.1).147,195,198 It is associated
with degenerative illness,199 neoplastic diseases,200 and ischemic injury to the brain,201,202
heart,203 liver,204,205 kidney,206 and intestine.205 Two typical different types of inducers of
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ferroptosis have been reported. The first type targeted phospholipid peroxidase glutathione
peroxidase 4 (GPX4).207 GPX4 converts potentially toxic lipid hydroperoxides (L-OOH) to
non-toxic lipid alcohols (L-OH). The inactivation of GPX4 inhibitors, such as (1S,3R)-RSL3
(hereafter referred to as RSL3), FINO2 and FIN56, induces the accumulation of L-OOH, a
signal of ferroptosis. The second type targets system Xc-, a cystine/glutamate antiporter.208 The
inhibition of system Xc- prevents exchange between cystine and glutamate and blocks cystine
import. The depletion of cystine in the cell inhibits the synthesis of glutathione. The limitation
of glutathione as the substrate inactivates GPX4 and induces the accumulation of L-OOH, and
subsequent ferroptosis. Other inducers have also been reported such as NRF2 inhibitor,209
peroxide,210 and external iron feeding.211 They are believed to relate with iron involved
oxidative stress. However, the relationship between iron involved oxidative stress and
ferroptosis is still unclear.
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Scheme 5.1. Mechanism of ferroptotic cell death.

Ferroptosis is initiated by the inhibition of system Xc or GPX4 activity, which ultimately leads to cell death. Lipid
peroxidation and ROS maybe responsible for the ferroptotic process. excess irons are the basis for ferroptosis execution.

Scheme 5.2. Intracellular iron metabolism.

Two solid pieces of evidence are shown the key role of iron involved in ferroptosis. Firstly,
external iron is prone to induce ferroptosis. Secondly, iron chelators, such as DFO, are strong
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inhibitors of ferroptosis. The enhancement of iron the concentrations in the cytosol of some
types of ferroptosis cells are also reported, although ferroptosis also presents in the cell without
significant change of iron the concentration.210 As a result of the unclear function of iron in
ferroptosis, the current hypothesis is usually attributed to iron as ROS inducer though Fenton
catalytic reaction simply (Scheme 5.2). Based on our previous studies about the intracellular
ferrous, we recently challenged this hypothesis. Firstly, Fe(II) and Fe(III) are different and
should have the different functions. Secondly, in the intracellular Fenton reaction, the
concentration of substrate, H2O2 (around 10-7 M range212) is significantly lower than the
concentration of the catalyst, iron (around 10-6 M) (Scheme 5.3). As a result, in the first step
of Fenton reaction process, Fe(II) is oxidized to Fe(III) and provides RO. radical. However, it
is far from reaching the second step, which means the main part of Fe(III) is hard to be reduced
by hydrogen peroxide in the biological condition due to the relatively low concentration of
both Fe(III) and hydrogen peroxide compared with the high concentration of Fe(II). Thirdly
and most importantly, most of the current research tools used for the study of the function of
iron in the ferroptosis rely on nonselective iron probes or in vitro analysis methods. For
example, the intracellular iron concentration detection is based on the non-selective metal
probe PhenGreen SK.213 We believe that the ferroptosis is correlates with Fe(III) directly,
whose oxidative character matches the oxidative stress induced behavior of ferroptosis. Fe(II)
serves as a reservoir of Fe(III) but it does not directly affect ferroptosis. The disorder of
Fe(II)/Fe(III) balance and accumulation of extra Fe(III) and attenuation of normal reduction
system of Fe(III) to Fe(II) by NRF2 pathway209,214-216 or metalloreductases, such as STEAP2,
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SDR2 and Dcytb induces labile Fe(III) level. The dysfunction of ferritin system maybe also
contribute the accumulation of the intracellular labile Fe(III).208,217-220
Scheme. 5.3 The mechanism of Fenton reaction catalyzed by iron.

5.2. Experiment design

Due to the sensitivity of the balance between Fe(II) and Fe(III) in the normal biological
condition and few methods available for probing the concentration of labile Fe(III) without
disturbing by labile Fe(II), we believed that it is highly necessary to design a detection method
to distinguish Fe(II) and Fe(III) clearly for the study of iron involved ferroptosis. To achieve
this, three criteria are required for cell experiment design: 1) comparison of external Fe(II)
with Fe(III), 2) interconversion between Fe(II) to Fe(III) by oxidation of Fe(II) or reduction of
Fe(III); 3) comparison of Fe(II) selective chelator with Fe(III) selective chelator.
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5.3. Validation of chemical tool in buffer

Validation of Fe(II) detection method based on ferene
Ferene related colorimetric analysis is widely used for colorimetric iron quantitation due to
its high specificity and sensitivity for Fe(II).221-224 Ferene binds Fe(II) iron, but not Fe(III) iron,
to form a complex that absorbs strongly at 592 nm, which can provide the fast detection method
for Fe(II). Its UV absorption at 592 nm shows the excellent linear relationship with the 1-10
μM of Fe(II) without disturbed by Fe(III) or other species in the HEPES buffer or PBS buffer
(Figure 5.1 and 5.2).
We also tried to use the available methods for the detection of Fe(III). However, neither
some reported fluorescent probes nor some reported colorimetric probes225 show poor
selectivity with Fe(II).
In our studies, the concentration of Fe(III) in buffer is detected by an indirect method through
reduction of all iron ion to Fe(II) by using 1% sodium ascorbate. And the cell samples are
tested by the commercial iron detection kit using the similar method based on the ferene-Fe(II)
complex.
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Uv-vis Spectrum for Ferene-Fe(II) complex
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Figure 5.1. UV-Vis Absorbance spectrum of the Fe(II)–ferene complex formed in the HEPES buffer (pH=7.4) with
increasing concentration of the standard FeCl2 from 0 to 10 μM.
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Figure 5.2. The UV-Vis absorption at 592 nm of the sample with vary concentration of Fe(II) or Fe(III), The increase in
absorbance of Fe(II) was linear between 1 and 10 μM for Fe(II) sample, in the contrast Fe(III) concentration have no
relationship with UV-Vis absorption at 592 nm.
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Study of intracellular total iron and Fe(II) without showing significant change in the
ferroptosis.
To understand the role of iron played in the ferroptosis, we measured intracellular Fe(II)
level in the HT-1080 cell based on our group reported naphthalimde Fe(II) fluorescence probe
(Figure 5.3). Surprisingly, we found that no significant change of the intracellular level of
Fe(II) was observed between ferroptosis group induced by erastin and the control vehicle. To
clarify this interesting phenomenon, we also lysis the cell to detect intracellular total iron and
Fe(II) (Figure 5.4). Similar results were obtained. However, the Fe(III) level was doubled in
the ferroptotic group, although the significant difference was not obtained due to the limitation
of the detection method. The data suggested Fe(III) might be “the real bad guy” in the
ferroptosis.

Figure 5.3. Detection of Fe(II) concentration in vivo for the HT-1080 cell by fluorescence probe. The image was
obtained for HT-1080 cell by of Fluorescence microscope. The control group was normal HT-1080 cell. (left) The
ferroptosis group was treated with 10 μM erastin 6 h and then stained with Fe(II) probe (right).
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Figure 5.4. Intracellular total iron and Fe(II) concentration comparison between control HT-1080 cell and ferroptosis
cell induced by erastin or RSL-3. The measurement was detected by the iron kit after deproteination by the
corresponding kit. erastin group cell treated with erastin 10 μM for 6 hours before lysis. RSL group treated with 0.5
μM RSL-3 for 6 hours before lysis. It needs to mention, the trypsin used for this experiment without EDTA, in order
to preventing disruption of iron detection. Data are mean cellular intensity ± s.e.m. across triplicates. No significant
difference was observed for the control group and ferroptosis group induced by erastin or RSL-3.

Determination and selection of iron chelators
Deferoxamine (DFO), deferasirox and deferiprone are used for the ion-chelation therapy
in the treatment of diseases including ischemic disease, atherosclerosis, neurodegenerative
diseases, and cancer. Recently, it was recognized that ferroptosis is a primary driver of ischemic
injury in some models. Based on the previous reports, the iron chelators were a type of strong
inhibitors for ferroptosis. However, these chelators are often used for chelation of both Fe(II)
and Fe(III) although these two ions have different redox characters.
To determine their selectivity, we conducted studies, as expected, DFO is a Fe(III) chelator
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(Figure 5.5). In the presence of DFO, the concentration of labile Fe(III) in the solution is very
low, the reduction of Fe(III) by Vc is very slow. However, DFO has the low binding affinity
with Fe(II). We screened chelators for Fe(II). Interestingly, all reported iron chelators are not
good for Fe(II). It is also interesting that binding with Fe(III) is more important for the
medication, although labile iron mainly is Fe(II).
Bipyrine is a good binder for Fe(II). Our studies supported the fact by the experiment of
bipyrine preventing more than 90% of Fe(II) to be oxidized by H2O2. (Figure 5.6) However,
bipyridine forms complexes with most transition metal ions without high selectivity for Fe(II).
Therefore, we try to find other chelators with more selectivity. Ferrozine and ferene are both
Fe(II) colorimetric probes showing high selectivity towards Fe(II). They share the same 3(pyridin-2-yl)-1,2,4-triazine core structure, which provides dinitrogen bonding site for Fe(II),
but they have poor cell permeability. To get cell permeable Fe(II) chelators, we design 5,6diphenyl-3-(pyridin-2-yl)-1,2,4-triazine (DPT) by removal of the two hydrophilic sulfonic
groups. They were synthesized in 2 steps (Scheme 1). DPT could form a chromatic complex
with Fe(II) with high binding affinity. The complex showed the symmetric peak at 554nm in
UV-Vis spectrum. DPT has no response towards Fe(III) based on the UV-Vis spectrum. And
then a competition assay between ferene and DPT towards Fe(II) was performed. A mixture of
equal concentration of ferene (50 μM) and DPT (50 μM) in the presence of Fe(II) produced a
wide peak at 574 nm. This comes from Fe(II)-DPT (554 nm) to Fe(II)-ferene (592 nm). It
indicated that both of DPT and ferene participated in the formation of the complex and DPT
and ferene had similar binding affinity towards Fe(II). (Figure 5.7) Although, due to the
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overlap of the UV-Vis spectrum and the formation of the more complicated complex from both
DPT and ferene with Fe(II), we cannot quantitate the effect of DPT towards the redox reaction
between Fe(II) and Fe(III). The chelators DFO for Fe(III), and DPT for Fe(II) are used for the
following biological study.
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Figure 5.5. DFO binding selectivity towards Fe(II) or Fe(III). If the sample treated with H2O2 or NaVc, the sample was
incubated at room temperature for 30 min.
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Figure 5.7. UV-Vis Absorbance spectrum of the Fe(II)-ferene complex formed in the HEPES buffer (pH=7.4)
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Scheme 5.3. The structure of ferrozine and ferene and Synthesis route for DPT

Identification of oxidant for oxidation of Fe(II) to Fe(III).
Besides chelation method, controlled redox conversion between Fe(II) and Fe(III) is another
possible way to distinguish the function of Fe(II) and Fe(III).
H2O2 is one of the oxidants which oxidized Fe(II) to Fe(III),but external H2O2 is
discomposed by catalase quickly and it induces apoptosis mainly instead of ferroptosis in
cells.226 Therefore, we tried to find other oxidants. After screening some peroxides, nitroxide
and hypochlorite (Scheme 5.4, Figure 5.8), tert-butyl hydroperoxide (tBuOOH) and tert-butyl
benzoperoxoate (BzOOtBu) could oxidize Fe(II) to Fe(III) (Figure 5.9). We chose tBuOOH
as the oxidant for Fe(II) for cellular studies due to its better water solubility and has been used
as a standard inducer for cellular oxidation pressure studies.227
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Scheme 5.4. The structure and abbreviated name towards the oxidants tested in the oxidation reaction for Fe(II).
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Figure 5.8. The selectivity of oxidation of Fe(II) for some oxidants. The reaction started from 10 μM Fe(II) and 50 μM
corresponding oxidant. After incubation for 10 min at room temperature, the residual Fe(II) was detected by ferene
method.

100

100
90

Fe(II) percentage

80
70
60
50
40
30
20
10
0
0

5

10

15

20

25

30

Time (min)
tBuOOH

BzOOtBu

H₂O₂

Figure 5.9. The kinetic curve of oxidation of Fe(II) for selected oxidants. The reaction started from 10 μM Fe(II) and 50
μM corresponding oxidant. After incubation for desired time at room temperature, the residual Fe(II) was detected by
ferene method. The oxidation reaction was quenched by addition of ferene at same time.

Identification of reductant for reduction of Fe(III) to Fe(II)
Natural reductants in the biological condition, such as ascorbic acid, glutathione, cysteine,
and NADPH can be used but they all participate many cellular bio-pathways with low
selectivity towards Fe(III). To overcome these issues, we tried to identify new selective
reductants. Based on our previous research on the N-O bond chemistry, since N-O bond
compound showed highly reaction selectivity towards Fe(II) over other metals and species.
Fine tuning its oxidation potential may produce optimal reductant for Fe(II). We found
phenylhydroxylamine (PhNHOH) showed desired properties (Figure 5.10). This compound is
easily synthesized from nitrobenzene in one step (Scheme 5.4). The reduction reaction between
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PhNHOH and Fe(III) is fast. Almost half of Fe(III) (49.3 %) converted to Fe(II) in 20 min at
room temperature when 10 μM Fe(III) with 50 μM PhNHOH in HEPES buffer contain 1%
DMSO was used. The conversion was increased to 89.7 % with 180 min reaction time. More
importantly, no significant reaction with either GSSG or H2O2 two main oxidants present with
the relatively high concentration in the cell occurred.

5.4 Cellular experiment
Scheme 5.4. Synthesis route of phenylhydroxylamine and the formation of product when Fe(II) was oxidized.

Comparing the function between Fe(II) and Fe(III)
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With all these chemical tools in hand, we started the intracellular experiments to elucidate
the functions of Fe(II) and Fe(III) in ferroptosis. The HT-1080 cell was chosen since it is
widely used in ferroptosis research as a model. Firstly, we probed the effect of Fe(II) and Fe(III)
through external addition of soluble Fe(II) or Fe(III) salt. Treatment with Fe(II) or Fe(III) at
50-400 μM can induce dose-dependent decrease of cell viability. However, the effect is cannot
be revised by treatment with 10 μM ferrostatin-1 (Fer-1). Ferroptosis is not the main type of
cell deaths induced by high concentration of iron. And then, we treated HT-1080 cell with both
Fe(II) or Fe(III) and reported ferroptosis inhibitor, RSL-3 (Figure 5.11). RSL-3 induced
ferroptosis on HT-1080 cell at 100 nM, by inhibition of GPX4 and accumulation of
intracellular oxidation of lipid. Our data showed that both Fe(II) and Fe(III) aggravated
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Figure 5.10. PhNHOH induced Fe(III) reduction. The reaction started from 10 μM Fe(III) and 50 μM PhNHOH. After
incubation for desired time at room temperature, the product Fe(II) was detected by ferene method.
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ferroptosis induced by RSL-3, and the LC50 decrease by 45% from control vehicle (0.138 μM).
We then changed ferroptosis inducer to erastin (Figure 5.12), which inhibitor system Xc-, a
cystine/glutamate antiporter presenting in the cell membrane. Erastin induced ferroptosis
through depletion of GSH, which is the substrate of GPX4. A similar cell viability was
performance. Both Fe(II) and Fe(III) enhanced ferroptosis induced by erastin. (LC50: 0.422 μM
(Fe(II)

and 0.545 μM

(Fe(III)

v.s. 1.99 μM(vehicle)) but no significant difference was observed

between Fe(II) and Fe(III). So, we lysed the cell and detected their intracellular iron
concentration (Figure 5.13). 35% of enhancement of total iron was observed for after treatment
by either 10 μM Fe(II) or 10 μM Fe(III). However, no matter treated with external Fe(II) or
Fe(III), the concentration of Fe(II) always increased significantly. In contrast, Fe(III) increased
marginally in both cases. This phenomenon can be explained by the regulation of intracellular
iron metabolism. And Fe(III) was reduced to Fe(II) by reductases on the cell membrane or in
the endosome. Only Fe(II) passed from cell membrane or released from endosome through
DMT1, which only selectively transported divalent iron, such as Fe(II). Both external Fe(II)
and Fe(III) were converted to Fe(II), passed the cell membrane and the re-equilibrium between
Fe(II) and Fe(III) was established again. As a result, both Fe(II) and Fe(III) showed the same
effect.
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Figure 5.11. Effect of Fe(II) and Fe(III) incubation on HT-1080 sensitivity to ferroptosis inducers RSL-3. The concentration
of Fe(II) or Fe(III) are fixed at 10 μM for the whole group of samples alternatively. And the concentration of RSL-3 was
doubling increase one by one in a group. The control vehicles were treated with the same concentration of pure DMSO instead
of the drug. Cell viability measured 24 h after compound treatment by MTT assay. Experiments were performed in triplicate
with biologically independent samples. Data are plotted as the mean ± s.d
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Figure 5.12. Effect of Fe(II) and Fe(III) incubation on HT-1080 sensitivity to ferroptosis inducers Erastin. The concentration
of Fe(II) or Fe(III) are fixed at 10 μM for the whole group of samples alternatively. And the concentration of Erastin was
doubling increase one by one in a group. 10 mM stock solution of Fe(II) and Fe(III) was prepared and dissolved in DI water
within half hour before cellular experiment. The stock solution of Erastin was diluted to 1,000-fold concentration
specifically for each desired concentration by DMSO. The control vehicles were treated with the same concentration of pure
DMSO instead of the drug. Cell viability measured 24 h after compound treatment by MTT assay. Experiments were
performed in triplicate with biologically independent samples. Data are plotted as the mean ± s.d
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Figure 5.13. Intracellular total iron, Fe(II) concentration and Fe(III) concentration comparison. The control group were treated
with 250 nM RSL-3 for 6 h. The Fe(II) group were treated with both 250 nM RSL-3 and 10 μM Fe(II) for 6h At the same time.
The Fe(III) group were treated with both 250 nM RSL-3 and 10 μM Fe(III) for 4h At the same time. After incubation time,
the cell was washed with PBS 3 times, suspended by trypsin without EDTA, and lysed by 1% NP-40. The measurement was
detected by the iron kit after deproteination by the corresponding kit. Erastin group cell treated with Erastin 10 μM for 6 hours
before lysis. Data are mean cellular intensity ± s.e.m. across triplicates.

Revealing the function between Fe(II) chelator and Fe(III) chelator
Without obtained the desired divergence between external Fe(II) and Fe(III) addition, due
to the kinetic equilibrium of intracellular iron metabolism pathway, we tried to minimize the
regulation of iron metabolism and disturb the balance between Fe(II) and Fe(III) in the living
cell. Selective iron chelators provide a way to selectively regulate either Fe(III) or Fe(II). We
treat the HT-1080 with both gradient concentration of RSL-3 and 10 μM chelators for 24 h
(Figure 5.14). The cell viability curve showed us that DFO, as a Fe(III) selective chelator,
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suppressed the cell death, and the LC50 increased more than four times (LC50 = 0.695 μM),
compared with control vehicle (LC50 = 0.138 μM). This result was consistent with the previous
studies.195 In contrast, decreasing intracellular Fe(II) by DPT, a Fe(II) selective chelator, had
almost no improvement for the cell viability (LC50 = 0.154 μM). We also checked another
ferroptosis target system Xc-, and the results confirmed DFO, Fe(III) chelator (Figure 5.15), is
the inhibitor for the ferroptosis (LC50 = 4.79 μM(DFO) v.s. 1.99 μM(vehicle)) instead of DPT, Fe(II)
chelator (LC50 = 2.29 μM(DPT)). This data supported our hypothesis, that Fe(III), as an oxidative
species in the cell, played a more important role in the ferroptosis with oxidation stress
character. Decreasing intracellular Fe(III) by chelator blocked the ferroptosis pathway, but
selectively removed intracellular Fe(II) has less effect for the ferroptosis, since Fe(II) is not
direct ferroptosis inducer.
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Fig. 5.14. Effect of iron chelator incubation on HT-1080 sensitivity to ferroptosis inducers RSL-3. The concentration of iron
chelators, DFO, BP or DPT, are fixed at 10 μM for the whole groups of samples alternatively. And the concentration of RSL3 was doubling increase one by one in a group. The positive control group was treated with 10 μM Fer-1. 10 mM stock solution
of DFO, BP, DPT or Fer-1 was prepared and dissolved in DMSO water within half hour before cellular experiment. The stock
solution of RSL-3 was diluted to 1,000-fold concentration specifically for each desired concentration by DMSO. The control
vehicles were treated with the same concentration of pure DMSO instead of the drug. Cell viability measured 24 h after
compound treatment by MTT assay. Experiments were performed in triplicate with biologically independent samples. Data
are plotted as the mean ± s.d.

109

120

Vehicle
Fer-1 10 μM
DFO 10 μM
BP 10 μM
DPT 10 μM

Cell Viability (%)

100

80

60

40

20

0
0.01

0.1

1

10

100

Erastin Concentration (μM)
Figure 5.15. Effect of Iron chelator incubation on HT-1080 sensitivity to ferroptosis inducers Erastin. The concentration of
iron chelators, DFO, BP or DPT, are fixed at 10 μM for the whole groups of samples alternatively. And the concentration of
RSL-3 was doubling increase one by one in a group. The positive control group was treated with 10 μM Fer-1. 10 mM stock
solution of DFO, BP, DPT and Fer-1 was prepared and dissolved in DMSO water within half hour before cellular
experiment. The stock solution of Erastin was diluted to 1,000-fold concentration specifically for each desired concentration
by DMSO. The control vehicles were treated with the same concentration of pure DMSO instead of the drug. Cell viability
measured 24 h after compound treatment by MTT assay. Experiments were performed in triplicate with biologically
independent samples. Data are plotted as the mean ± s.d.

Interconversion between intracellular Fe(II) and Fe(III)
After distinguishing the function of Fe(III) and Fe(II) by the chelator, the hypothesis that
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Fe(III) is an important player in ferroptosis was further verified by interconversion studies
between Fe(II) and Fe(III). tBuOOH, as Fe(II) oxidant, significantly aggravated the either
RSL-3 or erastin ferroptosis (Figure 5.16 and 5.17). It is noteworthy that unitary high
concentration of tBuOOH (100-200 μM) induced HT-1080 cell death without full recovery by
Fer-1, which indicated other types of cell death present in the high concentration range of
tBuOOH. This phenomenon has also been noticed by other groups.228
After treating HT-1080 with both 12.5 μM PhNHOH and gradient concentration of RSL-3
(Figure 5.16), the cell viability enhanced (LC50: 0.238 μM(PhNHOH) v.s 0.135 μM(vehicle)).
Cotreatment with erastin also confirmed PhNHOH as the inhibitor of ferroptosis (Figure 5.17).
(LC50: 8.84 μM(PhNHOH) v.s.1.99 μM(vehicle)). Then we further defined the dose-dependent
character for PhNHOH. When the concentration of PhNHOH increased from 10 to 50 μM, the
effect of inhibition continually enhanced, although high concentration showed cytotoxicity
from the compound (Figure 5.18 and 5.19). The significant dose-dependent behavior proved
PhNHOH as a new type of ferroptosis inhibitor, which targeted intracellular labile Fe(III), and
reduced it to relatively nontoxic Fe(II). In the current stage we have not optimized the structure
of PhNHOH, but we believe, based on its simple structure and convenient synthetic scheme, it
has a huge potential for further development and application in the biology and medicine as a
new type of iron inhibitor.
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Figure 5.16. Effect of co-culture incubation on HT-1080 sensitivity to ferroptosis inducers RSL-3. The concentration of
PhNHOH was fixed at 12.5 μM, and the concentration of tBuOOH was fixed at 20 μM for the whole groups of samples
alternatively. And the concentration of Erastin was doubling increase one by one in a group. The positive control group was
treated with 10 μM Fer-1. 1000-fold stock solution of PhNHOH, tBuOOH and Fer-1 was prepared and dissolved in DMSO
water within half hour before cellular experiment. The stock solution of RSL-3 was diluted to 1,000-fold concentration
specifically for each desired concentration by DMSO. The control vehicles were treated with the same concentration of pure
DMSO instead of the drug. Cell viability measured 24 h after compound treatment by MTT assay. Experiments were
performed in triplicate with biologically independent samples. Data are plotted as the mean ± s.d.
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Figure 5.17. Effect of co-culture incubation on HT-1080 sensitive to ferroptosis inducers Erastin. The concentration of
PhNHOH was fixed at 12.5 μM, and the concentration of tBuOOH was fixed at 20 μM for the whole groups of samples
alternatively. And the concentration of Erastin was doubling increase one by one in a group. The positive control group was
treated with 10 μM Fer-1. 1000-fold stock solution of PhNHOH, tBuOOH and Fer-1 was prepared and dissolved in DMSO
water within half hour before cellular experiment. The stock solution of Erastin was diluted to 1,000-fold concentration
specifically for each desired concentration by DMSO. The control vehicles were treated with the same concentration of pure
DMSO instead of the drug. Cell viability measured 24 h after compound treatment by MTT assay. Experiments were
performed in triplicate with biologically independent samples. Data are plotted as the mean ± s.d.

113

120
Vehicle
Fer-1 10 μM
PhNHOH 12.5 μM
PhNHOH 25 μM
PhNHOH 50 μM

Cell Viability (%)

100

80

60

40

20

0
1E-3

0.01

0.1

1

10

RSL-3 Concentration (μM)
Figure 5.18. Dose-dependent effect of PhNHOH incubation on HT-1080 sensitive to ferroptosis inducers RSL-3. The
concentration of PhNHOH is fixed at 12.5, 25 or 50 μM for the whole group of samples specifically, and the concentration of
RSL-3 was doubling increase one by one in a group. 1000-fold stock solution of PhNHOH was prepared and dissolved in
DMSO within half hour before cellular experiment. The positive control group was treated with 10 μM Fer-1. The cell viability
measured 24 h after compound treatment by MTT assay. Experiments were performed in triplicate with biologically
independent samples. Data are plotted as the mean ± s.d.
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Figure 5.19. Dose-dependent effect of PhNHOH incubation on HT-1080 sensitivity to ferroptosis inducers Erastin. The
concentration of PhNHOH is fixed at 12.5, 25 or 50 μM for the whole group of samples specifically, and the concentration of
RSL-3 was doubling increase one by one in a group. 1000-fold stock solution of PhNHOH was prepared and dissolved in
DMSO within half hour before cellular experiment. The positive control group was treated with 10 μM Fer-1. The cell viability
measured 24 h after compound treatment by MTT assay. Experiments were performed in triplicate with biologically
independent samples. Data are plotted as the mean ± s.d.

The relationship between iron and intracellular peroxide in ferroptosis
According to reported studies that iron participated in the ferroptosis through enhancement
of intracellular Fenton reaction and accumulation of ROS, especially L-OOH. Therefore, we
designed experiments to understand the relationship between iron and ROS or L-OOH. HT115

1080 cell was treated with a low concentration of RSL-3 (250 nM) for 6 hours to block GXP4
pathway and induced ferroptosis. And then the cell was suspended and added external Fe(II)
or Fe(III) to enhance the formation of ROS and L-OOH (Fig. 5.20). The samples treated with
both external Fe(II) and Fe(III) with right shifting peak indicating the enhancement of
formation of ROS compared with the control vehicle. As L-OOH played a more important role
in the ferroptosis, we also detected it by C11-BODIPY method. Both external Fe(II) and Fe(III)
induced L-OOH in the living cells. And then we added both external iron and iron chelators to
the suspended cell. The DPT as Fe(II) chelators, significantly reduced the concentration of both
ROS and L-OOH in the living cell, no matter external addition with Fe(II) or Fe(III). In contrast,
DFO as Fe(III) chelator, only responded toward external Fe(III). This phenomenon can be
explained by the abolishment of external Fe(III) by chelation outside of the cell. Interestingly,
the chelator of Fe(II) efficiently decreased of ROS and L-OOH but it showed few effects for
ferroptosis. In contrast, the chelator of Fe(III) inhibited ferroptosis with limited effect for ROS
and L-OOH abolishment induced by Fe(II). It should be careful to explain this data since the
external iron was applied for the experiment. However, the function of the Fenton reaction may
be overestimated in the ferroptosis. Currently, we don’t find another clear target for Fe(III) in
the ferroptosis, but we believe Fe(III) should participate other pathways of ferroptosis, except
playing the simply role as a catalyst of Fenton reaction.
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Figure 5.20. The comparison of formation of ROS and L-OOH in the living cell. HT-1080 cell was treated with a low
concentration of RSL-3 (250 nM) for 6 hours to block GXP4 pathway and induced ferroptosis, and then after the cell was
suspended, this cell was used as control vehicle. The ROS was measured by H2DCFA method. L-OOH was measured by C11BODIPY. The mean intensity ratio towards the control vehicle group was showed in the fig. After external treatment for iron
and iron chelator, the cell was cultured at 37 ℃ for 30 min. And then the fluorescences of samples are measured by
flowcytometry.

5.5. Conclusion

The data described herein clearly showed that labile Fe(III) is the real ferroptosis inducer
instead of labile Fe(II). We firstly reported the hydroxylamine as a ferroptosis inhibitor through
the reduction of Fe(III) to Fe(II). In contrast, tBuOOH, the oxidant of Fe(II), is ferroptosis
inducer through oxidation of Fe(II) to Fe(III). Removal of Fe(III) by the chelator of Fe(III)
inhibited the ferroptosis, but the chelator of Fe(II), as a strong inhibitor of Fenton reaction, has
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no significant relationship with ferroptosis. The function of Fenton reaction in the ferroptosis
may be overestimated. The real target of labile Fe(III) and the reason of imbalance between
Fe(II)/Fe(III) in the ferroptosis are worth for further research.

5.6. Experiment section

General Information: Commercial reagents were used as received unless otherwise stated.
Merck 60 silica gel was used for chromatography, and Whatman silica gel plates with
fluorescence F254 were used for thin-layer chromatography (TLC) analysis.
Spectroscopic Materials and Methods: Fluorescence emission spectra were obtained on a
SHIMADZU spectrofluorophotometer RF-5301pc. The UV absorption spectra were obtained
on a SHIMADZU UV-1800.
1

H and 13C NMR spectra were recorded on Bruker Avance 500 and Bruker tardis (sb300).

The signals in 1H and 13C NMR spectra were referenced to the residual peak of a deuterated
solvent.
Data for 1H are reported as follows: chemical shift (ppm), and multiplicity (s = singlet, d =
doublet, t = triplet, q = quartet, m = multiplet, br = broad). Data for 13C NMR are reported as
ppm.
Cell Culture: All cells were cultured in DMEM medium (Gibco) supplemented with 10% FBS,
2 mM Gluta MAX (Life Technologies), 100 U/mL penicillin (Life Technologies) and 100
μg/mL streptomycin (Life Technologies) at 37 °C in a humidified atmosphere containing 5%
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CO2. Due to the strong binding affinity between Fe(II) and Fe(III) with EDTA, trypsin used
for lysis in the whole project is excluded with EDTA.
Cell Viability Assay: Cell viability was determined by the MTT assay. Cells (5 × 104/well)
were seeded in a 96-well plate overnight before treatment with the corresponding compound
for designed time. After the exchange of the medium to pure DMEM, 20 μl of the MTT solution
(5 mg/ml) was added to each well and incubated at 37 °C for 2 h. The supernatant was removed,
and the insoluble formazan product was dissolved in 100 μl of DMSO. The absorbance of each
culture well was measured with a microplate reader (Molecular Devices, USA) at a wavelength
of 570 nm.
Intracellular Iron Measurement: Ten million HT-1080 cells were treated with 10 μM Erastin,
0.25 μM RSL3 or vehicle. Cells were harvested after 6 h and lysed using ice-cold PBS
containing 0.5% Nonidet P-40. Samples were centrifuged for 15 min at 4 °C at 17,000g. The
resulting supernatant was deproteinized using a deproteinizing kit (ab2047080, Abcam) and
kept on ice. The total iron and Fe(II) was determined using (Fluorometric - Green)
(QuantiChrom™ Iron Assay Kit DIFE-250) following the manufacturer's protocol.
Flow Cytometry Analysis: HT-1080 cell was treated with a low concentration of RSL-3 (250
nM) for 6 hours to block GXP4 pathway and induced ferroptosis, and then after the cell was
suspended, this cell was used as control vehicle. Another group was established on the control
vehicle with additional compound. The concentrations of Fe(II) and Fe(II) are 10 μM, and the
concentrations of DPT and DFO are 50 μM. DHCA was applied for ROS detection. C11
BODIPY was used for L-OOH detection. ROS and L-OOH levels were analyzed by flow
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cytometry and 10 K cells were counted for each condition. Mean fluorescence intensity for all
counted cells in each condition was obtained by BD Accuri C6 Plus flow cytometer.
Experiments were conducted in triplicate or quadruplicate.
Fluorescence Microscopy and Statistical Analysis: Zeiss Axio Observer. D1 outfitted with
HBO 100 microscopy illumination system (RhB channel: excitation, 555 nm; and emission,
580 nm) was used to take fluorescence images for Fe(II) probe in the described experiments
for the following statistical analysis. Cell images were collected from five different areas (four
quarters and center) in each of the three independent experiments. Fluorescence analysis as
described above using ImageJ.

Compound Synthesis

phenylhydroxylamine
To nitrobenzene (102.5 μl, 1 mmol) in 10 mL MeOH was added Zinc powder (130 mg, 2
mmol) and NH4Cl (64.2 mg, 1.2 mmol), then the mixture was heated to reflux and stirred for
30 min. After cooling to room temperature, the solid in solution was removed by filtration,
and the solvent was removed by rotavapor. The product was purified through column
chromatography and obtained as white cotton-like solid (89 mg, 82%). 1H NMR (300 MHz,
CDCl3): δ 6.48 (m, 2H), 7.04 (m, 3H), 7.32 (m, 2H). 13C NMR (500 MHz, CDCl3):149.3,
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128.9, 122.6, 114.9.

DPT
A mixture of picolinonitrile (104 mg,1 mmol), hydrazine hydrate (64 μl, 1 mmol) and ethanol
(5 ml) was reacted for 8 h at room temperature. The redundant ethanol was removed at room
temperature by vacuum. (2-pyridine) amidrazone intermediate was obtained which can be
detected by TLC. After dissolved the intermediate in another 5 ml ethanol, benzil (210 mg, 1
mmol) was added in to the flask, and then the reaction mixture stirred 8 h and reflux for 1h.
After cooling down, partial of the solvent was removed by rotavapor, the solid was filtered out
and wash with ethanol. After drying by oil pump, the product was obtained as the yellow crystal
(145 mg, 47%). 1H NMR (500 MHz, CDCl3): δ 7.35-7.50 (m, 7H), 7.63 (m, 2H), 7.69 (m, 2H),
7.94 (dd, J = 8.0 Hz, 4.0 Hz, 1H), 8.92(d, J = 0.5Hz, 1H), 8.93(d, J = 0.5Hz, 1H). 13C NMR
(500 MHz, CDCl3): δ 124.3, 125.5, 128.7, 129.7, 130.1, 130.8, 135.4, 137.8, 150.7, 153.0,
156.5, 156.7, 160.9.

1,2-diphenyldiazene 1-oxide
10 ml 10 mM phenylhydroxylamine was dissolved in HEPES (50 mM)/DMSO 90:10. 0.12
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mmol of FeCl3 was added in. After stirring 1 min, TLC indicate the consuming of the reactant.
The reaction mixture was extracted by EA (10 ml). The product was purified through column
chromatography and obtained as white solid. 1H NMR (500 MHz, CDCl3): δ 7.39 (dd, J = 6.0
Hz, 1.5 Hz, 1H) 7.41-7.60 (m, 5H), 8.18 (d, J = 7.5 Hz, 2H), 8.32(d, J= 8.0 Hz, 2H). 13C NMR
(500 MHz, CDCl3): δ 122.5, 125.7, 128.8, 128.9, 129.7, 131.8, 144.1, 148.5.
Flowcytometry data

Figure S5.1. The comparison of formation of ROS in the living cell. HT-1080 cell was treated with a low concentration of
RSL-3 (250 nM) for 6 hours to block GXP4 pathway and induced ferroptosis, and then after the cell was suspended, this cell
was used as control vehicle (black line). Another two group was established on the control vehicle with additional external
Fe(II) (blue line) or Fe(III) (green line) to measure the relationship between external iron and the formation of ROS.
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Figure S5.2. The comparison of formation of ROS in the living cell. HT-1080 cell was treated with a low concentration of
RSL-3 (250 nM) for 6 hours to block GXP4 pathway and induced ferroptosis, and then after the cell was suspended, this cell
was used as control vehicle (black line). Another three group was established on the control vehicle with additional external
Fe(II), (blue line), both external Fe(II) and DPT (orange line) and both external Fe(II) and DFO (deep blue line) to measure
the relationship between intracellular Fe(II) and Fe(III) and the formation of ROS.

Figure S5.3. The comparison of formation of ROS in the living cell. HT-1080 cell was treated with a low concentration of
RSL-3 (250 nM) for 6 hours to block GXP4 pathway and induced ferroptosis, and then after the cell was suspended, this cell
was used as control vehicle (black line). Another three group was established on the control vehicle with additional external
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Fe(III), (green line), both external Fe(III) and DPT (blue line) and both external Fe(II) and DFO (red line) to measure the
relationship between intracellular Fe(II) and Fe(III) and the formation of ROS.

Figure S5.4. The comparison of formation of L-OOH in the living cell. HT-1080 cell was treated with a low concentration of
RSL-3 (250 nM) for 6 hours to block GXP4 pathway and induced ferroptosis, and then after the cell was suspended, this cell
was used as control vehicle (black line). Another two group was established on the control vehicle with additional external
Fe(II) (blue line) or Fe(III) (pink line) to measure the relationship between external iron and the formation of L-OOH.
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Figure S5.5. The comparison of formation of L-OOH in the living cell. HT-1080 cell was treated with a low concentration of
RSL-3 (250 nM) for 6 hours to block GXP4 pathway and induced ferroptosis, and then after the cell was suspended, this cell
was used as control vehicle (black line). Another three group was established on the control vehicle with additional external
Fe(II), (pink line), both external Fe(II) and DPT (blue line) and both external Fe(II) and DFO (red line) to measure the
relationship between intracellular Fe(II) and Fe(III) and the formation of L-OOH.

Figure S 5.6. The comparison of formation of L-OOH in the living cell. HT-1080 cell was treated with a low concentration of
RSL-3 (250 nM) for 6 hours to block GXP4 pathway and induced ferroptosis, and then after the cell was suspended, this cell
was used as control vehicle (black line). Another three group was established on the control vehicle with additional external
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Fe(III), (green line), both external Fe(III) and DPT (blue line) and both external Fe(II) and DFO (red line) to measure the
relationship between intracellular Fe(II) and Fe(III) and the formation of L-OOH.
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